

PCT Box Seq.
418 Rec'd PCT/PTO 10 APR 1999

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

ATTORNEY'S DOCKET NUMBER

TRANSMITTAL LETTER TO THE UNITED STATES
DESIGNATED/ELECTED OFFICE (DO/EO/US)
CONCERNING A FILING UNDER 35 U.S.C. 371

GC516-2-US

U.S. APPLICATION NO. (If known, see 37 CFR 1.5)

09/284327

INTERNATIONAL APPLICATION NO.

PCT/US98/26552

INTERNATIONAL FILING DATE

12-14-98

PRIORITY DATE CLAIMED

12-16-97

TITLE OF INVENTION Novel EGI-III-Like Enzymes, DNA Encoding Such Enzymes and Methods
for Producing Such Enzymes

APPLICANT(S) FOR DO/EO/US Benjamin S. Bower; Timothy Fowler; Jay Ian Phillips

Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:

1. ☒ This is a **FIRST** submission of items concerning a filing under 35 U.S.C. 371.
2. ☐ This is a **SECOND** or **SUBSEQUENT** submission of items concerning a filing under 35 U.S.C. 371.
3. ☒ This express request to begin national examination procedures (35 U.S.C. 371(f)) at any time rather than delay examination until the expiration of the applicable time limit set in 35 U.S.C. 371(b) and PCT Articles 22 and 39(1).
4. ☐ A proper Demand for International Preliminary Examination was made by the 19th month from the earliest claimed priority date.
5. ☒ A copy of the International Application as filed (35 U.S.C. 371(c)(2))
 - a. ☐ is transmitted herewith (required only if not transmitted by the International Bureau).
 - b. ☐ has been transmitted by the International Bureau.
 - c. ☒ is not required, as the application was filed in the United States Receiving Office (RO/US).
6. ☐ A translation of the International Application into English (35 U.S.C. 371(c)(2)).
7. ☒ Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3))
 - a. ☐ are transmitted herewith (required only if not transmitted by the International Bureau).
 - b. ☐ have been transmitted by the International Bureau.
 - c. ☒ have not been made; however, the time limit for making such amendments has NOT expired
 - d. ☐ have not been made and will not be made.
8. ☐ A translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).
9. ☒ An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)).
10. ☐ A translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).

Items 11. to 16. below concern document(s) or information included:


11. ☐ An Information Disclosure Statement under 37 CFR 1.97 and 1.98.
12. ☐ An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.
13. ☐ A **FIRST** preliminary amendment.
☐ A **SECOND** or **SUBSEQUENT** preliminary amendment.
14. ☐ A substitute specification.
15. ☐ A change of power of attorney and/or address letter.
16. ☐ Other items or information:

U.S. APPLICATION NO. (37 CFR 1.53) 09/284327		INTERNATIONAL APPLICATION NO. US98/26552		ATTORNEYS DOCKET NUMBER GC516-2-IIS																					
<p>17. XXI The following fees are submitted:</p> <p>BASIC NATIONAL FEE (37 CFR 1.492 (a) (1) - (5)) :</p> <p>Neither international preliminary examination fee (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO and International Search Report not prepared by the EPO or JPO \$970.00</p> <p>International preliminary examination fee (37 CFR 1.482) not paid to USPTO but International Search Report prepared by the EPO or JPO \$840.00</p> <p>International preliminary examination fee (37 CFR 1.482) not paid to USPTO but international search fee (37 CFR 1.445(a)(2)) paid to USPTO \$760.00</p> <p>International preliminary examination fee paid to USPTO (37 CFR 1.482) but all claims did not satisfy provisions of PCT Article 33(1)-(4) \$670.00</p> <p>International preliminary examination fee paid to USPTO (37 CFR 1.482) and all claims satisfied provisions of PCT Article 33(1)-(4) \$96.00</p> <p>ENTER APPROPRIATE BASIC FEE AMOUNT =</p>				<p>CALCULATIONS PTO USE ONLY</p>																					
<p>Surcharge of \$130.00 for furnishing the oath or declaration later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492(e)).</p>				<p>\$ 840.00</p>																					
<table border="1"> <thead> <tr> <th>CLAIMS</th> <th>NUMBER FILED</th> <th>NUMBER EXTRA</th> <th>RATE</th> </tr> </thead> <tbody> <tr> <td>Total claims</td> <td>30 - 20 =</td> <td></td> <td>X \$18.00</td> </tr> <tr> <td>Independent claims</td> <td>3 - 3 =</td> <td></td> <td>X \$78.00</td> </tr> <tr> <td colspan="3">MULTIPLE DEPENDENT CLAIM(S) (if applicable)</td> <td>+ \$260.00</td> </tr> <tr> <td colspan="3">TOTAL OF ABOVE CALCULATIONS =</td> <td>\$1,020.00</td> </tr> </tbody> </table>				CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE	Total claims	30 - 20 =		X \$18.00	Independent claims	3 - 3 =		X \$78.00	MULTIPLE DEPENDENT CLAIM(S) (if applicable)			+ \$260.00	TOTAL OF ABOVE CALCULATIONS =			\$1,020.00	<p>\$ 180.00</p> <p>\$ -0-</p> <p>\$</p>	
CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE																						
Total claims	30 - 20 =		X \$18.00																						
Independent claims	3 - 3 =		X \$78.00																						
MULTIPLE DEPENDENT CLAIM(S) (if applicable)			+ \$260.00																						
TOTAL OF ABOVE CALCULATIONS =			\$1,020.00																						
<p>Reduction of 1/2 for filing by small entity, if applicable. A Small Entity Statement must also be filed (Note 37 CFR 1.9, 1.27, 1.28).</p>				<p>\$</p>																					
<p>SUBTOTAL =</p>				<p>\$</p>																					
<p>Processing fee of \$130.00 for furnishing the English translation later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492(f)).</p>				<p>\$</p>																					
<p>TOTAL NATIONAL FEE =</p>				<p>\$</p>																					
<p>Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 per property +</p>				<p>\$</p>																					
<p>TOTAL FEES ENCLOSED =</p>				<p>\$</p>																					
				<p>Amount to be: refunded \$</p>																					
				<p>charged \$1,020.00</p>																					

- a. ☐ A check in the amount of \$_____ to cover the above fees is enclosed.
- b. ☒ Please charge my Deposit Account No. 07-1048 in the amount of \$1,020.00 to cover the above fees.
A duplicate copy of this sheet is enclosed.
- c. ☐ The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any
overpayment to Deposit Account No. _____. A duplicate copy of this sheet is enclosed.

NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.

SEND ALL CORRESPONDENCE TO:



SIGNATURE:

Christopher L. Stone

NAME

35,696

REGISTRATION NUMBER

PCT Rec'd 10 APR 1999 09/284327

NOVEL EGIII-LIKE ENZYMES, DNA ENCODING SUCH ENZYMES
AND METHODS FOR PRODUCING SUCH ENZYMES

BACKGROUND OF THE INVENTION

5 1. Field of the Invention

The present invention is directed to novel cellulase compositions which share unique highly conserved regions with a known useful cellulase. More specifically, the present invention relates to a series of newly discovered enzymes from fungi and bacteria which are related by virtue of having at least one of five important conserved amino acid sequences
10 which are also present in EGIII.

2. State of the Art

Cellulases are enzymes which are capable of hydrolysis of the β -D-glucosidic linkages in celluloses. Cellulolytic enzymes have been traditionally divided into three major
15 classes: endoglucanases, exoglucanases or cellobiohydrolases and β -glucosidases (Knowles, J. et al., (1987), *TIBTECH* 5, 255-261); and are known to be produced by a large number of bacteria, yeasts and fungi.

Primary among the applications that have been developed for the use of cellulolytic enzymes are those involving degrading (wood)cellulose pulp into sugars for (bio)ethanol
20 production, textile treatments like 'stone washing' and 'biopolishing', and in detergent compositions. Thus, cellulases are known to be useful in the treatment of mechanical pulp (see e.g., PCT Publication No. WO 92/16687). Additionally, cellulases are known to be useful as a feed additive (see e.g., PCT Publication No. WO 91/04673) and in grain wet milling.

25 Of primary importance, however, cellulases are used in the treatment of textiles, i.e., in detergent compositions for assisting in the removal of dirt or grayish cast (see e.g., Great Britain Application Nos. 2,075,028, 2,095,275 and 2,094,826 which illustrate improved cleaning performance when detergents incorporate cellulase) or in the treatment of textiles prior to sale to improve the feel and appearance of the textile. Thus, Great Britain
30 Application No. 1,358,599 illustrates the use of cellulase in detergents to reduce the harshness of cotton containing fabrics and cellulases are used in the treatment of textiles to recondition used fabrics by making their colors more vibrant (see e.g., The Shizuoka Prefectural Hammamatsu Textile Industrial Research Institute Report, Vol. 24, pp. 54-61 (1986)). For example, repeated washing of cotton containing fabrics results in a grayish cast
35 to the fabric which is believed to be due to disrupted and disordered fibrils, sometimes called

"pills", caused by mechanical action. This greyish cast is particularly noticeable on colored fabrics. As a consequence, the ability of cellulase to remove the disordered top layer of the fiber and thus improve the overall appearance of the fabric has been of value.

Thus, cellulases have been shown to be effective in many industrial processes.

5 Accordingly, there has been a trend in the field to search for specific cellulase compositions or components which have particularly effective performance profiles with respect to one or more specific applications. In this light, cellulases produced (expressed) in fungi and bacteria have been subject of attention. For example, cellulase produced by certain fungi such as *Trichoderma* spp. (especially *Trichoderma longibrachiatum*) have been given much
10 attention because a complete cellulase system capable of degrading crystalline forms of cellulose is readily produced in large quantities via fermentation procedures. This specific cellulase complex has been extensively analyzed to determine the nature of its specific components and the ability of those components to perform in industrial processes. For example, Wood et al., "Methods in Enzymology", 160, 25, pages 234 et seq. (1988), disclose
15 that complete fungal cellulase systems comprise several different enzyme classifications including those identified as exo-cellobiohydrolases (EC 3.2.1.91) ("CBH"), endoglucanases (EC 3.2.1.4) ("EG"), and β -glucosidases (EC 3.2.1.21) ("BG"). The fungal cellulase classifications of CBH, EG and BG can be further expanded to include multiple components within each classification. U.S. Patent No. 5,475,101 (Ward et al.) discloses the purification
20 and molecular cloning of one particularly useful enzyme called EGIII which is derived from *Trichoderma longibrachiatum*.

PCT Publication No. WO 94/14953 discloses endoglucanases which are encoded by a nucleic acid which comprises any one of a series of DNA sequences, each having 20 nucleotides.

25 Ooi et al., *Curr. Genet.*, Vol. 18, pp. 217-222 (1990) disclose the cDNA sequence coding for endoglucanase F1-CMC produced by *Aspergillus aculeatus* which contains the amino acid strings>NNLWG, ELMIW and GTEPFT. Sakamoto et al., *Curr. Genet.*, Vol. 27, pp. 435-439 (1995) discloses the cDNA sequence encoding the endoglucanase CMCase-1 From *Aspergillus kawachii* IFO 4308 which contains the amino acid strings ELMIW and
30 GTEPFT. Ward et al., discloses the sequence of EGIII having the amino acid strings>NNLWG, ELMIW and GTEPFT. Additionally, two cellulase sequences, one from *Erwinia carotovara* and *Rhodothermus marinus* are disclosed in Saarilahti et al., *Gene*, Vol. 90, pp. 9-14 (1990) and Hreggvidsson et al., *Appl. Environ. Microb.*, Vol. 62, No. 8, pp. 3047-3049 (1996) which contain the amino acid string ELMIW. However, none of these references
35 discloses or suggests that these amino acid strings have any particular relevance in

identifying or isolating other cellulases, and particularly fail to suggest that such cellulases are obtainable from such diverse organisms as bacteria, Actinomycetes and other filamentous fungi.

Despite knowledge in the art related to many cellulase compositions having
5 applications in some or all of the above areas, there is a continued need for new cellulase compositions having improved characteristics which are useful in, for example, treating textiles, as a component of detergent compositions, in the treatment of pulp and paper, food processing, and in the conversion of biomass. Thus, while there has been significant improvement in terms of the understanding of cellulase compositions and their activities,
10 there remains a need for alternative cellulase compositions which retain the beneficial effects of known cellulase compositions. In response to this need, Applicants herein surprisingly discovered that novel microbial enzymes which are related to an enzyme known to be useful in industrial applications, i.e., EGIII, can be detected and obtained by virtue of the presence of unique conserved sequences therein.

SUMMARY OF THE INVENTION

The present invention was the product of intensive research by the inventors hereof related to determining whether valuable enzymes could be detected by using a routine PCR techniques based on important and newly discovered conserved sequences found within the
20 sequence of EGIII. Surprisingly, the inventors hereof discovered that these conserved sequences are found not only in EGIII, but also in enzymes derived from organisms from classifications as diverse as filamentous fungi, bacteria and Actinomycete. By utilizing the present invention, Applicants have isolated a number of genes encoding novel cellulases which are related to EGIII in that they possess the conserved regions described herein.

25 It is an object of the invention to provide novel cellulase compositions which have useful properties when utilized in industrial processes such as textile treatment, laundering of textiles, feed additive technology, baking and food processing, grain wet milling and biomass conversion.

It is another object of the invention to provide evidence for an extensive classification
30 of industrially useful cellulases which are related in structure and function to EGIII.

It is yet another object of the invention to provide for analogs to EGIII which may have additional improved properties in, for example, specific activity, performance in textile treatment, substrate specificity, thermostability, oxidative resistance and alkaline performance profile.

-- 4 --

According to the present invention, an enzyme having cellulolytic activity is provided comprising an amino acid sequence comprising therein an amino acid string selected from the group consisting of:

- (a) Asn-Asn-(Leu/Phe/Lys/Ile)-Trp-Gly
- (b) Glu-(Leu/Phe/Ile)-Met-Ile-Trp
- (c) Gly-Thr-Glu-Pro-Phe-Thr;
- (d) (Ser/Tyr/Cys/Trp/Thr/Asn/Lys/Arg)-(Val/Pro)-(Lys/Ala)-(Ser/Ala)-(Tyr/Phe);
- (e) Lys-Asn-Phe-Phe-Asn-Tyr.

In a preferred embodiment of the present invention the enzyme is an endoglucanase. Also preferably, the enzyme is derived from a fungal or bacterial source, most preferably from a filamentous fungus.

In another embodiment of the present invention, a DNA encoding the enzyme according to the invention is provided. Also provided are expression vectors comprising that DNA, host cells transformed with such expression vectors and enzymes produced by such host cells.

In yet another embodiment of the present invention, a method of detecting an EGIII-like enzyme is provided comprising the steps of:

(1) preparing a DNA primer which encodes an amino acid string selected from the group consisting of:

- (a) Asn-Asn-(Leu/Phe/Lys/Ile)-Trp-Gly
- (b) Glu-(Leu/Phe/Ile)-Met-Ile-Trp
- (c) Gly-Thr-Glu-Pro-Phe-Thr;
- (d) (Ser/Tyr/Cys/Trp/Thr/Asn/Lys/Arg)-(Val/Pro)-(Lys/Ala)-(Ser/Ala)-(Tyr/Phe); and
- (e) Lys-Asn-Phe-Phe-Asn-Tyr.

(2) preparing genomic DNA from an organism of interest;

(3) mixing the primer according to step (1) with the genomic DNA according to step (2) under conditions appropriate to facilitate identification and isolation of a DNA fragment comprising a gene encoding an EGIII like cellulase.

In a preferred embodiment of this aspect of the invention, the method above is utilized to detect an EGIII like enzyme and comprises labeling said DNA primer and mixing in said step (3) under conditions of standard stringency to permit hybridization of said DNA primer with a complementary sequence within the genomic DNA; and subsequent identification and isolation of the gene corresponding to said complementary sequence from

-- 5 --

said organism of interest which encodes an EGIII cellulase. In another preferred embodiment of this aspect of the invention, step (3) comprises initiating one or more PCR reactions between said DNA primers and said genomic DNA, and identifying and isolating an appropriate fragment produced during such PCR reaction which corresponds to a gene
 5 encoding an EGIII like enzyme.

Also within the scope of the present invention is the use of the EGIII like enzyme in textile treatment, e.g., in laundry detergent or stonewashing compositions, in the reduction of biomass, in the production of feed additives or treatment of feed, in the treatment of wood pulp for the production of paper or pulp based products, and in the treatment of starch during
 10 grain wet milling or dry milling to facilitate the production of glucose, high fructose corn syrup and/or alcohol.

An advantage of the present invention is that a repeatable protocol has been discovered which permits rapid and simple isolation of genes encoding valuable cellulase enzymes.
 15

BRIEF DESCRIPTION OF THE DRAWINGS

Fig. 1 illustrates the amino acid sequence of EGIII from *Trichoderma longibrachiatum*.

Fig. 2 illustrates branches of the fungal phylogenetic tree as interpreted by the NCBI.

Fig. 3 illustrates a comparison of a 102 residue peptide taken from the sequence of
 20 EGIII with a corresponding peptide from *Fusarium equiseti* [FUSEQIN]; *Gliocladium roseum* [GLIOIN]; *Acremonium brachypenium* [ACRHYP0](hypothetical protein sequence without intron); *Aspergillus kawachii* [ASPKAWA1]; *Aspergillus aculeatus* [ASPACU1]; *Humicola insolens* [HUMIN]; *Actinomyces (streptomyces) sp. 11AG8* [11AG8IN]; *Erwinia carotovora* [ERWCARIN]; *Gliocladium roseum* [GLIO314]; *Gliocladium roseum* [GLIOHYP](hypothetical
 25 protein sequence without intron); *Humicola grisea* [HGRIS]; *Rhodothermus marinus* [RHMARIN]; *Streptomyces lividans* [SLIVINS]; *Penicillium notatum* [PENNOT]; *Phanerochaete chrysosporium* [PHANHYP0](hypothetical protein sequence without intron); *Emericella desertoru* [EMDESHYP](hypothetical protein sequence without intron); *Chaetomium brasiliense* and [CHBRAS]; *Myceliophthora thermophila* [MYCINS](only 27
 30 amino acids).

Fig. 4 illustrates a chart showing the percent similarity of protein sequences compared in Fig. 3.

Fig. 5 illustrates the DNA sequence of EGIII from *Trichoderma longibrachiatum* without introns.

Fig. 6 illustrates an alignment of the full length sequence of 20 EGIII-like cellulases in alignment with EGIII, indicating equivalent residues based on primary sequence modeling, including those derived from *Trichoderma reesei*, *Hypocrea schweinitzii*, *Aspergillus aculeatus*, *Aspergillus kawachii* (1), *Aspergillus kawachii* (2), *Aspergillus oryzae*, *Humicola grisea*, *Humicola insolens*, *Chaetomium brasiliense*, *Fusarium equiseti*, *Fusarium javanicum* (1), *Fusarium javanicum* (2), *Gliocladium roseum* (1), *Gliocladium roseum* (2), *Gliocladium roseum* (3), *Gliocladium roseum* (4), *Memnoniella echinata*, *Emericella desertoru*, *Actinomyces* 11AG8, *Streptomyces lividans* CelB, *Rhodothermus marinus*, and *Erwinia carotovora*.

DETAILED DESCRIPTION OF THE INVENTION

The present invention relates to a purified EGIII like enzyme having cellulolytic activity and which is obtained from organisms other than *Trichoderma spp.*, *Humicola spp.*, and *Erwinia carotovora* and *Rhodothermus marinus*.

Within the specification, certain terms are disclosed which are defined below so as to clarify the nature of the claimed invention.

"Cellulase" is a well classified category of enzymes in the art and includes enzymes capable of hydrolyzing cellulose polymers to shorter celooligosaccharide oligomers, cellobiose and/or glucose. Common examples of cellulase enzymes include exo-cellobiohydrolases and endoglucanases and are obtainable from many species of cellulolytic organisms, particularly including fungi and bacteria.

"EGIII" cellulase refers to the endoglucanase component described in Ward et al., U.S. Patent No. 5,475,101 and Proceedings on the Second TRICEL Symposium on *Trichoderma Reesei* Cellulases And Other Hydrolases, Suominen & Reinikainen eds., Espoo Finland (1993), pp. 153-158 (Foundation for Biotechnical and Industrial Fermentation Research, Vol. 8). As discussed therein, EGIII is derived from *Trichoderma reesei* (*longibrachiatum*) and is characterized by a pH optimum of about 5.8, an isoelectric point (pI) of from about 7.4 and a molecular weight of about 25 kD. The enzyme commonly referred to as EGII from *Trichoderma reesei* has been previously referred to in the literature by the nomenclature EGIII by some authors, but that enzyme differs substantially from the enzyme defined herein as EGIII in terms of molecular weight, pI and pH optimum.

"EG-III like enzyme", "EGIII like protein" or "EGIII like cellulase" according to the present invention means, on the one hand, an enzyme having cellulolytic activity which comprises an amino acid sequence comprising therein an amino acid string selected from the group consisting of one or more of:

-- 7 --

- (a) Asn-Asn-(Leu/Phe/Lys/Ile)-Trp-Gly
- (b) Glu-(Leu/Phe/Ile)-Met-Ile-Trp
- (c) Gly-Thr-Glu-Pro-Phe-Thr;
- (d) (Ser/Tyr/Cys/Trp/Thr/Asn/Lys/Arg)-(Val/Pro)-(Lys/Ala)-(Ser/Ala)-
5 (Tyr/Phe); and
- (e) Lys-Asn-Phe-Phe-Asn-Tyr.

In one embodiment, the enzyme of the invention further has significant structural and/or sequence homology to EGIII. Thus, in one aspect of this embodiment of the invention, the enzyme has at least 30%, preferably at least 40% and most preferably at least 60% amino
10 acid identity to EGIII. However, it should be recognized that homology alone is often not an appropriate measure for whether a particular enzyme identified by the methods described herein represents an EGIII like enzyme. Accordingly, while homologous enzymes are indeed detected by the methods described and exemplified herein, the degree of homology should not be seen as limiting the scope of the invention.

15 It is contemplated that the EGIII like enzymes of the invention may be found in many organisms which produce cellulases. However, likely sources of EGIII like enzyme include those derived from a bacterial or fungal sources, and more particularly, from an Actinomycete, a Bacillus or a filamentous fungus. In a preferred embodiment, the enzyme is derived from the filamentous fungal family Metazoa, preferably Euscomycetes. Within
20 Metazoa, fungal phylogenetic classifications which produce EGIII like enzymes include the mitosporic Pyrenomycetes (including Acremonium), Sordariales (including Thielavia), Hypocreales (including Nectriaceae such as Fusarium, Necitia, Verticillium, Myrothecium and Gliocladium; and Hypocrea) and Eurotiales (including mitosporic Trichocomaceae such as Aspergillus and Penicillium).

25 The Euscomycete preferably belongs to Diaporthales, Halosphaerales, Microascales, Ophiostomatales, Phyllachorales, Sordariales or Xylariales. Also preferably, the Euscomycete belongs to Hypocreales comprising Clavicipitaceae, Melanosporaceae, Nectriaceae, Niessliaceae or Mitosporic Hypocreales. Further preferably, the Euscomycete belongs to Hypocreaceae, wherein said Hypocreaceae does not comprise Trichoderma.

30 Most preferably, the Euscomycete is *Gliocladium spp.*, *Fusarium spp.*, *Acremonium spp.*, *Myceliophthora spp.*, *Verticillium spp.*, *Myrothecium spp.*, *Penicillium spp.*, *Chaetomium spp.*, *Emercella spp.*, and *Phanerochaete spp.* Specific organisms which are contemplated as possessing EGIII like enzymes include *Chaetomium thermophilum var. therm.*, *Chaetomium atrobrunneum*, *Chaetomium brasiliense*, *Chaetomium globosum*, *Chaetomium vitellium*,
35 *Paecilomyces lilacinus*, *Chaetomium thermophilum var. dissitum*, *Humicola insolens*,

Humicola brevis, *Memnoniella echinata*, *Fusarium equiseti*, *Fusarium oxysporum*, *Fusarium stilboides*, *Myceliophthora thermophila*, *Fusarium javanicum*, *Humicola grisea* var. *thermoidea*, *Stibella thermophila*, *Melanocarpus albomyces*, *Arthrobotrys superba*, *Myceliophthora hinunilea*, *Chaetomium pachypodiodes*, *Myrothecium verrucaria*, *Penicillium*
 5 *crysogenum*, *Malbranchea sulfurea*, *Lunulospora curvula*, *Emericella desertorum*, *Acremonium strictum*, *Cylindrocarpon heteronema*, and *Ulocladium chartarum*.

Within the Actinomycetes, *Streptomyces* has been shown to possess EGIII like enzymes. Where the species of origin of the EGIII like cellulase is *Aspergillus*, the specific species is an *Aspergillus* comprising *A. aeneus*, *A. anthodesmis*, *A. aureofulgens*, *A.*
 10 *aureolatus*, *A. avenaceus*, *A. awamorii*, *A. bisporus*, *A. brunneouniseriatus*, *A. campestris*, *A. caesiellus*, *A. candidus*, *A. carbonarius*, *A. carneus*, *A. cervinus*, *A. clavatoflavus*, *A. clavatoanicus*, *A. clavatus*, *A. conicus*, *A. conjunctus*, *A. crustosus*, *A. deflectus*, *A. dimorphicus*, *A. eburneocreameus*, *A. egyptiacus*, *A. ellipticus*, *A. elongatus*, *A. ficuum*, *A. flaschentraegeri*, *A. flavus*, *A. fumigatus*, *A. giganteus*, *A. glaucus*, *A. gorakhpurensis*, *A.*
 15 *gracilis*, *A. iizuke*, *A. itaconicus*, *A. japonicus*, *A. kambarensis*, *A. kanagawaensis*, *A. lanosus*, *A. leporis*, *A. longivesica*, *A. mellinus*, *A. multicolor*, *A. niger*, *A. nomius*, *A. nutans*, *A. ochraceus*, *A. pallidus*, *A. panamensis*, *A. parasiticus*, *A. parvulus*, *A. penicillioides*, *A. phialisepticus*, *A. phoenicis*, *A. proliferans*, *A. pulvinus*, *A. puniceus*, *A. raperi*, *A. recurvatus*, *A. restrictus*, *A. shirousami*, *A. sojiae*, *A. sparsus*, *A. subolivaceus*, *A. subsessilis*, *A. tamarii*,
 20 *A. terreus*, *A. terricola*, *A. thomii*, *A. tubingensis*, *A. unguis*, *A. unilateralis*, *A. ustus*, *A. versicolor*, *A. wentii*, *A. xerophilus*, *A. zonatus*, *A. sp.*

Another embodiment comprising EGIII like enzymes according to the invention may be obtained according to the following methods. DNA primers are constructed which encode an amino acid sequence selected from the group consisting of one or more of:

- 25 (a) Asn-Asn-(Leu/Phe/Lys/Ile)-Trp-Gly
- (b) Glu-(Leu/Phe/Ile)-Met-Ile-Trp
- (c) Gly-Thr-Glu-Pro-Phe-Thr;
- (d) (Ser/Tyr/Cys/Trp/Thr/Asn/Lys/Arg)-(Val/Pro)-(Lys/Ala)-(Ser/Ala)-(Tyr/Phe); and
- 30 (e) Lys-Asn-Phe-Phe-Asn-Tyr.

and used to obtain DNA, and genes, encoding enzymes having cellulolytic activity according to established methods.

In the preferred embodiment according to this aspect of the invention, degenerate primers are prepared corresponding to one or more of the above peptides. The peptides are
 35 combined with a genomic DNA from a target organism (i.e., the organism in which the EGIII

like enzyme is sought) under conditions suitable to initiate a standard PCR reaction. In this embodiment, it is advantageous to select degenerate primers corresponding to peptides (a) and/or (d) plus primers corresponding to (c) and/or (e) and perform PCR with those peptides. After the PCR reaction has been performed, the resulting DNA is run on a polyacrylamide gel and bands corresponding in size to the EGIII fragment comprising peptides (a) and/or (d) in addition to (c) and/or (e), i.e., those in the 400-1000 base pair range, are selected out. These fragments are pooled and reamplified using primers corresponding to peptides (a) and/or (d) plus primers corresponding to peptide (b) or, alternatively, using primers corresponding to peptide (c) and/or (e) plus primers corresponding to peptide (b). Strong bands of the expected size (in the case of EGIII like enzymes, the bands will correspond to the approximately 250-500 base pair range) are excised and sequenced. The sequence is then used to design exact match primers and these primers used with the technique referred to as rapid amplification of genomic DNA ends to obtain the full length gene, see e.g., Mizobuchi et al., *BioTechniques*, Vol. 15, No. 2, pp. 215-216 (1993).

However, it is also possible to use the degenerate DNA's as hybridization probes against a genomic library obtained from a target organism to analyze whether a given fragment correlates to a similar sequence in the target organism. A useful hybridization assay is as follows: Genomic DNA from a particular target source is fragmented by digestion with a restriction enzyme(s), e.g., EcoR I, Hind III, Bam HI, Cla I, Kpn I, Mlu I, Spe I, Bgl II, Nco I, Xba I, Xho I and Xma I (supplied by New England Biolabs, Inc., Beverly, MA and Boehringer Mannheim) according to the manufacturer's instructions. The samples are then electrophoresed through an agarose gel (such as, for example, 0.7% agarose) so that separation of DNA fragments can be visualized by size. The gel may be briefly rinsed in distilled H₂O and subsequently depurinated in an appropriate solution (such as, for example, 0.25M HCl) with gentle shaking followed by denaturation for 30 minutes (in, for example, 0.4 M NaOH). A renaturation step may be included in which the gel is placed in 1.5 M NaCl, 1M Tris, pH 7.0 with gentle shaking for 30 minutes. The DNA should then be transferred onto an appropriate positively charged membrane, for example the *Maximum Strength Nytran Plus* membrane (Schleicher & Schuell, Keene, N.H.), using a transfer solution (such as, for example, 6XSSC (900 mM NaCl, 90 mM trisodium citrate). After the transfer is complete, generally at about 2 hours or greater, the membrane is rinsed and air dried at room temperature after using a rinse solution (such as, for example, 2X SSC[2X SSC = 300 mM NaCl, 30 mM trisodium citrate]). The membrane should then be prehybridized, (for approximately 2 hours or more) in a suitable prehybridization solution (such as, for example, an aqueous solution containing per 100 mls: 30-50 mls formamide, 25 mls of 20X SSPE (1X

SSPE = 0.18 M NaCl, 1 mM EDTA, 10 mM NaH_2PO_4 , pH 7.7), 2.5 mls of 20% SDS, 1 ml of 10 mg/ml sheared herring sperm DNA).

A DNA probe corresponding to the peptide sequences above should be isolated by electrophoresis in an agarose gel, the fragment excised from the gel and recovered from the excised agarose. This purified fragment of DNA is then labeled (using, for example, the *Megaprime* labeling system according to the instructions of the manufacturer to incorporate P^{32} in the DNA (Amersham International plc, Buckinghamshire, England)). The labeled probe is denatured by heating to 95° C for 5 minutes and immediately added to the prehybridization solution above containing the membrane. The hybridization reaction should proceed for an appropriate time and under appropriate conditions, for example, for 18 hours at 37° C with gentle shaking. The membrane is rinsed (for example, in 2X SSC/0.3% SDS) and then washed with an appropriate wash solution and with gentle agitation. The stringency desired will be a reflection of the conditions under which the membrane (filter) is washed.

Specifically, the stringency of a given reaction (i.e., the degree of homology necessary for successful hybridization) will largely depend on the washing conditions to which the filter from the Southern Blot is subjected after hybridization. "Low-stringency" conditions as defined herein will comprise washing a filter from a Southern Blot with a solution of 0.2X SSC/0.1% SDS at 20° C for 15 minutes. Standard-stringency conditions comprise a further washing step comprising washing the filter from the Southern Blot a second time with a solution of 0.2X SSC/0.1% SDS at 37° C for 30 minutes.

The DNA which hybridizes with the DNA primers outlined above and thus identified by this method a corresponding EGIII encoding gene may be isolated by routine methods and used to express the corresponding EGIII like enzyme according to routine techniques. A preferred cloning procedure comprises the rapid amplification of genomic DNA ends described in, e.g., Mizobuchi et al., *BioTechniques*, Vol. 15, No. 2, pp. 215-216 (1993). Upon obtaining the cloned gene, routine methods for insertion of the DNA into a vector which can then be transformed into a suitable host cell are used. Culturing the transformed host cell under appropriate conditions then results in production of the EGIII like cellulase which can be obtained, purified and prepared as necessary for a particular application.

The EGIII like enzymes of the invention are preferably isolated or purified. In the context of the present invention, purification or isolation generally means that the EGIII like cellulase is altered from its natural state by virtue of separating the EGIII like cellulase from some or all of the naturally occurring substituents with which it is associated in nature, e.g., the source organism or other cellulases or enzymes expressed by the source organism in conjunction with the EGIII cellulase. Similarly, the EGIII like enzymes of the invention may be

-- 11 --

combined with other components which are not naturally present in the natural state.

Isolation of purification may be accomplished by art recognized separation techniques such as ion exchange chromatography, affinity chromatography, hydrophobic separation, dialysis, protease treatment, ammonium sulphate precipitation or other protein salt precipitation techniques, centrifugation, size exclusion chromatography, filtration, microfiltration, gel electrophoresis or separation on a gradient to remove whole cells, cell debris, impurities, extraneous proteins, or enzymes undesired in the final composition.

"Cellulose containing fabric" means any sewn or unsewn fabrics, yarns or fibers made of cotton or non-cotton containing cellulose or cotton or non-cotton containing cellulose blends including natural cellulosics and manmade cellulosics (such as jute, flax, ramie, rayon, and lyocell). Included under the heading of manmade cellulose containing fabrics are regenerated fabrics that are well known in the art such as rayon. Other manmade cellulose containing fabrics include chemically modified cellulose fibers (e.g. cellulose derivatized by acetate) and solvent-spun cellulose fibers (e.g. lyocell). Specifically included within the definition of cellulose containing fabric is any yarn or fiber made of such materials. Cellulose containing materials are often incorporated into blends with materials such as synthetic fibers and natural non-cellulosic fibers such as wool and silk.

"Cotton-containing fabric" means sewn or unsewn fabrics, yarns or fibers made of pure cotton or cotton blends including cotton woven fabrics, cotton knits, cotton denims, cotton yarns, raw cotton and the like. When cotton blends are employed, the amount of cotton in the fabric is preferably at least about 35 percent by weight cotton. When employed as blends, the companion material employed in the fabric can include one or more non-cotton fibers including cellulosic or synthetic fibers such as polyamide fibers (for example, nylon 6 and nylon 66), acrylic fibers (for example, polyacrylonitrile fibers), and polyester fibers (for example, polyethylene terephthalate), polyvinyl alcohol fibers (for example, Vinyon), polyvinyl chloride fibers, polyvinylidene chloride fibers, polyurethane fibers, polyurea fibers and aramid fibers.

"Stonewashing composition" means a formulation for use in stonewashing cellulose containing fabrics. Stonewashing compositions are used to modify cellulose containing fabrics prior to presentation for consumer sale, i.e., during the manufacturing process. In contrast, detergent compositions are intended for the cleaning of soiled garments.

"Stonewashing" means the treatment of cellulose containing fabric with a cellulase solution under agitating and cascading conditions, i.e., in a rotary drum washing machine, to impart a "stonewashed" appearance to the denim. The cellulase solution according to the instant invention will functionally replace the use of stones in such art recognized methods,

either completely or partially. Methods for imparting a stonewashed appearance to denim are described in U.S. Patent No. 4,832,864 which is incorporated herein by reference in its entirety. Generally, stonewashing techniques have been applied to indigo dyed cotton denim.

5 "Detergent composition" means a mixture which is intended for use in a wash medium for the laundering of soiled cellulose containing fabrics. In the context of the present invention, such compositions may include, in addition to cellulases and surfactants, additional hydrolytic enzymes, builders, bleaching agents, bleach activators, bluing agents and fluorescent dyes, caking inhibitors, masking agents, cellulase activators, antioxidants,
10 and solubilizers. Such compositions are generally used for cleaning soiled garments and are not used during the manufacturing process, in contrast to stonewashing compositions. Detergent compositions comprising cellulase are described in, for example, Clarkson et al., U.S. Patent No. 5,290,474 and EP Publication No. 271 004, incorporated herein by reference.

15 "Derivative" means a protein which is derived from a precursor protein (e.g., the native protein) by addition of one or more amino acids to either or both the C- and N-terminal end, substitution of one or more amino acids at one or a number of different sites in the amino acid sequence, deletion of one or more amino acids at either or both ends of the protein or at one or more sites in the amino acid sequence, or insertion of one or more amino
20 acids at one or more sites in the amino acid sequence. The preparation of an enzyme derivative is preferably achieved by modifying a DNA sequence which encodes for the native protein, transformation of that DNA sequence into a suitable host, and expression of the modified DNA sequence to form the derivative enzyme. The derivative of the invention includes peptides comprising altered amino acid sequences in comparison with a precursor
25 enzyme amino acid sequence (e.g., a wild type or native state enzyme), which peptides retain a characteristic enzyme nature of the precursor enzyme but which have altered properties in some specific aspect. For example, a cellulase derivative may have an increased pH optimum or increased temperature or oxidative stability but will retain its characteristic cellulolytic activity. Similarly, derivatives according to the present invention
30 include a cellulose binding domain portions of which have either been added, removed or modified in such a way so as to significantly impair or enhance its cellulose binding ability. It is contemplated that derivatives according to the present invention may be derived from a DNA fragment encoding a cellulase derivative wherein the functional activity of the expressed cellulase derivative is retained. For example, a DNA fragment encoding a
35 cellulase may further include a DNA sequence or portion thereof encoding a hinge or linker

attached to the cellulase DNA sequence at either the 5' or 3' end wherein the functional activity of the encoded cellulase domain is retained. Derivative further includes chemical modification to change the characteristics of the enzyme.

"Expression vector" means a DNA construct comprising a DNA sequence which is operably linked to a suitable control sequence capable of effecting the expression of the DNA in a suitable host. Such control sequences may include a promoter to effect transcription, an optional operator sequence to control transcription, a sequence encoding suitable ribosome-binding sites on the mRNA, and sequences which control termination of transcription and translation. Different cell types are preferably used with different expression vectors. A preferred promoter for vectors used in *Bacillus subtilis* is the AprE promoter; a preferred promoter used in *E. coli* is the Lac promoter, a preferred promoter used in *Saccharomyces cerevisiae* is *PGK1*, a preferred promoter used in *Aspergillus niger* is *glaA*, and a preferred promoter for *Trichoderma reesei* (*longibrachiatum*) is *cbhl*. The vector may be a plasmid, a phage particle, or simply a potential genomic insert. Once transformed into a suitable host, the vector may replicate and function independently of the host genome, or may, under suitable conditions, integrate into the genome itself. In the present specification, plasmid and vector are sometimes used interchangeably. However, the invention is intended to include other forms of expression vectors which serve equivalent functions and which are, or become, known in the art. Thus, a wide variety of host/expression vector combinations may be employed in expressing the DNA sequences of this invention. Useful expression vectors, for example, may consist of segments of chromosomal, non-chromosomal and synthetic DNA sequences such as various known derivatives of SV40 and known bacterial plasmids, e.g., plasmids from *E. coli* including col E1, pCR1, pBR322, pMb9, pUC 19 and their derivatives, wider host range plasmids, e.g., RP4, phage DNAs e.g., the numerous derivatives of phage λ , e.g., NM989, and other DNA phages, e.g., M13 and filamentous single stranded DNA phages, yeast plasmids such as the 2 μ plasmid or derivatives thereof, vectors useful in eukaryotic cells, such as vectors useful in animal cells and vectors derived from combinations of plasmids and phage DNAs, such as plasmids which have been modified to employ phage DNA or other expression control sequences. Expression techniques using the expression vectors of the present invention are known in the art and are described generally in, for example, Sambrook et al., *Molecular Cloning: A Laboratory Manual, Second Edition*, Cold Spring Harbor Press (1989). Often, such expression vectors including the DNA sequences of the invention are transformed into a unicellular host by direct insertion into the genome of a particular species through an integration event (see e.g., Bennett & Lasure, *More Gene Manipulations in Fungi*, Academic

Press, San Diego, pp. 70-76 (1991) and articles cited therein describing targeted genomic insertion in fungal hosts, incorporated herein by reference).

"Host strain" or "host cell" means a suitable host for an expression vector comprising DNA according to the present invention. Host cells useful in the present invention are
 5 generally procaryotic or eucaryotic hosts, including any transformable microorganism in which expression can be achieved. Specifically, host strains may be *Bacillus subtilis*, *Escherichia coli*, *Trichoderma reesei* (*longibrachiatum*), *Saccharomyces cerevisiae* or *Aspergillus niger*. Host cells are transformed or transfected with vectors constructed using recombinant DNA techniques. Such transformed host cells are capable of both replicating
 10 vectors encoding swollenin and its variants (mutants) or expressing the desired peptide product. In a preferred embodiment according to the present invention, "host cell" means both the cells and protoplasts created from the cells of *Trichoderma sp.*

"Signal sequence" means a sequence of amino acids bound to the N-terminal portion of a protein which facilitates the secretion of the mature form of the protein outside of the
 15 cell. This definition of a signal sequence is a functional one. The mature form of the extracellular protein lacks the signal sequence which is cleaved off during the secretion process.

"DNA vector" means a nucleotide sequence which comprises one or more DNA fragments or DNA variant fragments encoding an EGIII like enzyme or derivatives described
 20 above which can be used, upon transformation into an appropriate host cell, to cause expression of the EGIII like cellulase.

"Functionally attached to" means that a regulatory region, such as a promoter, terminator, secretion signal or enhancer region is attached to a structural gene and controls the expression of that gene.

25 The present invention relates to the expression, purification and/or isolation and use of EGIII like enzymes and derivatives of such EGIII like enzyme. These enzymes are preferably prepared by recombinant methods utilizing the gene identified and isolated according to the methods described above. However, enzymes for use in the present invention may be obtained by other art recognized means such as purification from natural
 30 isolates.

It is conceived by the inventors that the microorganism to be transformed for the purpose of expressing an EGIII like enzyme according to the present invention may advantageously comprise a strain derived from *Trichoderma sp.* Thus, a preferred mode for preparing EGIII like enzymes according to the present invention comprises transforming a
 35 *Trichoderma sp.* host cell with a DNA construct comprising at least a fragment of DNA

encoding a portion or all of the EGIII like enzyme detected as described above. The DNA construct will generally be functionally attached to a promoter. The transformed host cell is then grown under conditions so as to express the desired protein. Subsequently, the desired protein product is purified to substantial homogeneity.

5 However, it may in fact be that the best expression vehicle for a given DNA encoding an EGIII like enzyme may differ. Thus, it may be that it will be most advantageous to express a protein in a transformation host which bears phylogenetic similarity to the source organism for the EGIII like enzyme. Accordingly, the present description of a *Trichoderma spp.* expression system is provided for illustrative purposes only and as one option for expressing
10 the EGIII like enzyme of the invention. One of skill in the art, however, may be inclined to express the DNA encoding EGIII like enzyme in a different host cell if appropriate and it should be understood that the source of the EGIII like enzyme should be considered in determining the optimal expression host. Additionally, the skilled worker in the field will be capable of selecting the best expression system for a particular gene through routine
15 techniques utilizing the tools available in the art.

In one embodiment, the strain comprises *T. reesei (longibrachiatum)* which is a useful strain for obtaining overexpressed protein. For example, RL-P37, described by Sheir-Neiss et al. in *Appl. Microbiol. Biotechnology*, 20 (1984) pp. 46-53 is known to secrete elevated amounts of cellulase enzymes. Functional equivalents of RL-P37 include *Trichoderma*
20 *reesei (longibrachiatum)* strain RUT-C30 (ATCC No. 56765) and strain QM9414 (ATCC No. 26921). It is contemplated that these strains would also be useful in overexpressing EGIII like enzymes.

Where it is desired to obtain the EGIII like cellulase in the absence of potentially detrimental native cellulolytic activity, it is useful to obtain a *Trichoderma* host cell strain
25 which has had one or more cellulase genes deleted prior to introduction of a DNA construct or plasmid containing the DNA fragment encoding the EGIII like enzyme. Such strains may be prepared by the method disclosed in U.S. Patent No. 5,246,853 and WO 92/06209, which disclosures are hereby incorporated by reference. By expressing an EGIII like enzyme in a host microorganism that is missing one or more cellulase genes, the identification and
30 subsequent purification procedures are simplified. Any gene from *Trichoderma sp.* which has been cloned can be deleted, for example, the *cbh1*, *cbh2*, *egl1*, and *egl3* genes as well as those encoding EGIII and/or EGV protein (see e.g., U.S. Patent No. 5,475,101 and WO 94/28117, respectively).

Gene deletion may be accomplished by inserting a form of the desired gene to be
35 deleted or disrupted into a plasmid by methods known in the art. The deletion plasmid is

then cut at an appropriate restriction enzyme site(s), internal to the desired gene coding region, and the gene coding sequence or part thereof replaced with a selectable marker. Flanking DNA sequences from the locus of the gene to be deleted or disrupted, preferably between about 0.5 to 2.0 kb, remain on either side of the selectable marker gene. An appropriate deletion plasmid will generally have unique restriction enzyme sites present therein to enable the fragment containing the deleted gene, including flanking DNA sequences, and the selectable marker gene to be removed as a single linear piece.

A selectable marker must be chosen so as to enable detection of the transformed fungus. Any selectable marker gene which is expressed in the selected microorganism will be suitable. For example, with *Trichoderma sp.*, the selectable marker is chosen so that the presence of the selectable marker in the transformants will not significantly affect the properties thereof. Such a selectable marker may be a gene which encodes an assayable product. For example, a functional copy of a *Trichoderma sp.* gene may be used which if lacking in the host strain results in the host strain displaying an auxotrophic phenotype.

In a preferred embodiment, a *pyr4⁻* derivative strain of *Trichoderma sp.* is transformed with a functional *pyr4* gene, which thus provides a selectable marker for transformation. A *pyr4⁻* derivative strain may be obtained by selection of *Trichoderma sp.* strains which are resistant to fluoroorotic acid (FOA). The *pyr4* gene encodes orotidine-5'-monophosphate decarboxylase, an enzyme required for the biosynthesis of uridine. Strains with an intact *pyr4* gene grow in a medium lacking uridine but are sensitive to fluoroorotic acid. It is possible to select *pyr4⁻* derivative strains which lack a functional orotidine monophosphate decarboxylase enzyme and require uridine for growth by selecting for FOA resistance. Using the FOA selection technique it is also possible to obtain uridine requiring strains which lack a functional orotate pyrophosphoribosyl transferase. It is possible to transform these cells with a functional copy of the gene encoding this enzyme (Berges and Barreau, *Curr. Genet.*, 19, 1991, pp. 359-365). Selection of derivative strains is easily performed using the FOA resistance technique referred to above, and thus, the *pyr4* gene is preferably employed as a selectable marker.

To transform *pyr4⁻* *Trichoderma sp.* so as to be lacking in the ability to express one or more cellulase genes, a single DNA fragment comprising a disrupted or deleted cellulase gene is then isolated from the deletion plasmid and used to transform an appropriate *pyr⁻* *Trichoderma* host. Transformants are then identified and selected based on their ability to express the *pyr4* gene product and thus complement the uridine auxotrophy of the host strain. Southern blot analysis is then carried out on the resultant transformants to identify and

-- 17 --

confirm a double crossover integration event which replaces part or all of the coding region of the genomic copy of the gene to be deleted with the *pyr4* selectable markers.

Although the specific plasmid vectors described above relate to preparation of *pyr*⁻ transformants, the present invention is not limited to these vectors. Various genes can be deleted and replaced in the *Trichoderma* sp. strain using the above techniques. In addition, any available selectable markers can be used, as discussed above. In fact, any *Trichoderma* sp. gene which has been cloned, and thus identified, can be deleted from the genome using the above-described strategy.

As stated above, the host strains used are derivatives of *Trichoderma* sp. which lack or have a nonfunctional gene or genes corresponding to the selectable marker chosen. For example, if the selectable marker of *pyr4* is chosen, then a specific *pyr4*⁻ derivative strain is used as a recipient in the transformation procedure. Similarly, selectable markers comprising *Trichoderma* sp. genes equivalent to the *Aspergillus nidulans* genes *amdS*, *argB*, *trpC*, *niaD* may be used. The corresponding recipient strain must therefore be a derivative strain such as *argB*⁻, *trpC*⁻, *niaD*⁻, respectively.

DNA encoding the EGIII like enzyme is then prepared for insertion into an appropriate microorganism. According to the present invention, DNA encoding a EGIII like enzyme comprises all of the DNA necessary to encode for a protein which has functional cellulolytic activity. The DNA fragment or DNA variant fragment encoding the EGIII like enzyme or derivative may be functionally attached to a fungal promoter sequence, for example, the promoter of the *cbh1* or *egl1* gene.

It is also contemplated that more than one copy of DNA encoding a EGIII like enzyme may be recombined into the strain to facilitate overexpression. The DNA encoding the EGIII like cellulase may be prepared by the construction of an expression vector carrying the DNA encoding the cellulase. The expression vector carrying the inserted DNA fragment encoding the EGIII like cellulase may be any vector which is capable of replicating autonomously in a given host organism or of integrating into the DNA of the host, typically a plasmid. In preferred embodiments two types of expression vectors for obtaining expression of genes are contemplated. The first contains DNA sequences in which the promoter, gene coding region, and terminator sequence all originate from the gene to be expressed. Gene truncation may be obtained where desired by deleting away undesired DNA sequences (e.g., coding for unwanted domains) to leave the domain to be expressed under control of its own transcriptional and translational regulatory sequences. A selectable marker is also contained on the vector allowing the selection for integration into the host of multiple copies of the novel gene sequences.

The second type of expression vector is preassembled and contains sequences required for high level transcription and a selectable marker. It is contemplated that the coding region for a gene or part thereof can be inserted into this general purpose expression vector such that it is under the transcriptional control of the expression cassettes promoter and terminator sequences. For example, pTEX is such a general purpose expression vector. Genes or part thereof can be inserted downstream of the strong *cbh1* promoter.

In the vector, the DNA sequence encoding the EGIII like enzyme of the present invention should be operably linked to transcriptional and translational sequences, i.e., a suitable promoter sequence and signal sequence in reading frame to the structural gene.

The promoter may be any DNA sequence which shows transcriptional activity in the host cell and may be derived from genes encoding proteins either homologous or heterologous to the host cell. The signal peptide provides for extracellular production of the EGIII like enzyme or derivatives thereof. The DNA encoding the signal sequence is preferably that which is naturally associated with the gene to be expressed, however the signal sequence from any suitable source, for example an exo-cellobiohydrolase or endoglucanase from *Trichoderma*, is contemplated in the present invention.

The procedures used to ligate the DNA sequences coding for the EGIII like enzyme of the present invention with the promoter, and insertion into suitable vectors are well known in the art.

The DNA vector or construct described above may be introduced in the host cell in accordance with known techniques such as transformation, transfection, microinjection, microporation, biolistic bombardment and the like.

In the preferred transformation technique, it must be taken into account that the permeability of the cell wall to DNA in *Trichoderma sp.* is very low. Accordingly, uptake of the desired DNA sequence, gene or gene fragment is at best minimal. There are a number of methods to increase the permeability of the *Trichoderma sp.* cell wall in the derivative strain (i.e., lacking a functional gene corresponding to the used selectable marker) prior to the transformation process.

The preferred method in the present invention to prepare *Trichoderma sp.* for transformation involves the preparation of protoplasts from fungal mycelium. The mycelium can be obtained from germinated vegetative spores. The mycelium is treated with an enzyme which digests the cell wall resulting in protoplasts. The protoplasts are then protected by the presence of an osmotic stabilizer in the suspending medium. These stabilizers include sorbitol, mannitol, potassium chloride, magnesium sulfate and the like. Usually the

concentration of these stabilizers varies between 0.8 M to 1.2 M. It is preferable to use about a 1.2 M solution of sorbitol in the suspension medium.

Uptake of the DNA into the host *Trichoderma sp.* strain is dependent upon the calcium ion concentration. Generally between about 10 mM CaCl_2 and 50 mM CaCl_2 is used in an uptake solution. Besides the need for the calcium ion in the uptake solution, other items generally included are a buffering system such as TE buffer (10 Mm Tris, pH 7.4; 1 mM EDTA) or 10 mM MOPS, pH 6.0 buffer (morpholinepropanesulfonic acid) and polyethylene glycol (PEG). It is believed that the polyethylene glycol acts to fuse the cell membranes thus permitting the contents of the medium to be delivered into the cytoplasm of the *Trichoderma sp.* strain and the plasmid DNA is transferred to the nucleus. This fusion frequently leaves multiple copies of the plasmid DNA tenderly integrated into the host chromosome.

Usually a suspension containing the *Trichoderma sp.* protoplasts or cells that have been subjected to a permeability treatment at a density of 10^8 to 10^9 /ml, preferably 2×10^8 /ml are used in transformation. A volume of 100 microliters of these protoplasts or cells in an appropriate solution (e.g., 1.2 M sorbitol; 50 mM CaCl_2) are mixed with the desired DNA. Generally a high concentration of PEG is added to the uptake solution. From 0.1 to 1 volume of 25% PEG 4000 can be added to the protoplast suspension. However, it is preferable to add about 0.25 volumes to the protoplast suspension. Additives such as dimethyl sulfoxide, heparin, spermidine, potassium chloride and the like may also be added to the uptake solution and aid in transformation.

Generally, the mixture is then incubated at approximately 0°C for a period of between 10 to 30 minutes. Additional PEG is then added to the mixture to further enhance the uptake of the desired gene or DNA sequence. The 25% PEG 4000 is generally added in volumes of 5 to 15 times the volume of the transformation mixture; however, greater and lesser volumes may be suitable. The 25% PEG 4000 is preferably about 10 times the volume of the transformation mixture. After the PEG is added, the transformation mixture is then incubated at room temperature before the addition of a sorbitol and CaCl_2 solution. The protoplast suspension is then further added to molten aliquots of a growth medium. This growth medium permits the growth of transformants only. Any growth medium can be used in the present invention that is suitable to grow the desired transformants. However, if *Pyr*⁺ transformants are being selected it is preferable to use a growth medium that contains no uridine. The subsequent colonies are transferred and purified on a growth medium depleted of uridine.

At this stage, stable transformants may be distinguished from unstable transformants by their faster growth rate and the formation of circular colonies with a smooth, rather than

ragged outline on solid culture medium lacking uridine. Additionally, in some cases a further test of stability may be made by growing the transformants on solid non-selective medium (i.e. containing uridine), harvesting spores from this culture medium and determining the percentage of these spores which will subsequently germinate and grow on selective medium lacking uridine.

In a particular embodiment of the above method, the EGIII like enzymes or derivatives thereof are recovered in active form from the host cell after growth in liquid media either as a result of the appropriate post translational processing of the novel EGIII like enzyme or derivatives thereof.

The expressed EGIII like enzyme may be recovered from the medium by conventional techniques including separations of the cells from the medium by centrifugation, filtration, and precipitation of the proteins in the supernatant or filtrate with a salt, for example, ammonium sulphate. Additionally, chromatography procedures such as ion exchange chromatography or affinity chromatography may be used. Antibodies (polyclonal or monoclonal) may be raised against the natural purified EGIII like enzyme, or synthetic peptides may be prepared from portions of the EGIII like enzyme molecule and used to raise polyclonal antibodies.

Treatment of textiles according to the present invention contemplates textile processing or cleaning with a composition comprising a cellulase. Such treating includes, but is not limited to, stonewashing, modifying the texture, feel and/or appearance of cellulose containing fabrics or other techniques used during manufacturing or cleaning/reconditioning of cellulose containing fabrics. Additionally, treating within the context of this invention contemplates the removal of "immature" or "dead" cotton, from cellulosic fabric or fibers. Immature cotton is significantly more amorphous than mature cotton and results in a lesser quality fabric when present due to, for example, uneven dyeing. The composition contemplated in the present invention further includes a cellulase component for use in washing of a soiled manufactured cellulose containing fabric. For example, the cellulase may be used in a detergent composition for washing laundry. Detergent compositions useful in accordance with the present invention include special formulations such as pre-wash, pre-soak and home-use color restoration compositions. Such treating compositions, as described herein, may be in the form of a concentrate which requires dilution or in the form of a dilute solution or form which can be applied directly to the cellulose containing fabric. General treatment techniques for cellulase treatment of textiles are described in, for example, EP Publication No. 220 016 and GB Application Nos. 1,368,599 and 2,095,275.

Treatment of a cellulosic material according to the present invention further contemplates the treatment of animal feed, pulp and/or paper, food and grain for purposes known in the art. For example, cellulase is known to increase the value of animal feed, improve the drainability of wood pulp, enhance food products and reduce fiber in grain during the grain wet milling process or dry milling process.

Treating according to the instant invention comprises preparing an aqueous solution which contains an effective amount of cellulase together with other optional ingredients including, for example, a buffer, a surfactant, and/or a scouring agent. An effective amount of cellulase enzyme composition is a concentration of cellulase enzyme sufficient for its intended purpose. Thus, for example, an "effective amount" of cellulase in a stonewashing composition according to the present invention is that amount which will provide the desired effect, e.g., to produce a worn and faded look in the seams and on fabric panels. Similarly, an "effective amount" of cellulase in a composition intended for improving the feel and/or appearance of a cellulose containing fabric is that amount which will produce measurable improvements in the feel, e.g., improving the smoothness of the fabric, or appearance, e.g., removing pills and fibrils which tend to reduce the sharpness in appearance of a fabric. The amount of cellulase employed is also dependent on the equipment employed, the process parameters employed (the temperature of the cellulase treatment solution, the exposure time to the cellulase solution, and the like), and the cellulase activity (e.g., a particular solution will require a lower concentration of cellulase where a more active cellulase composition is used as compared to a less active cellulase composition). The exact concentration of cellulase in the aqueous treatment solution to which the fabric to be treated is added can be readily determined by the skilled artisan based on the above factors as well as the desired result. In stonewashing processes, it has generally been preferred that the cellulase be present in the aqueous treating solution in a concentration of from about 0.5 to 5,000 ppm and most preferably about 10 to 200 ppm total protein. In compositions for the improvement of feel and/or appearance of a cellulose containing fabric, it has generally been preferred that the cellulase be present in the aqueous treating solution in a concentration of from about 0.1 to 2000 ppm and most preferably about 0.5 to 200 ppm total protein.

In a preferred treating embodiment, a buffer is employed in the treating composition such that the concentration of buffer is sufficient to maintain the pH of the solution within the range wherein the employed cellulase exhibits activity which, in turn, depends on the nature of the cellulase employed. The exact concentration of buffer employed will depend on several factors which the skilled artisan can readily take into account. For example, in a preferred embodiment, the buffer as well as the buffer concentration are selected so as to

-- 22 --

maintain the pH of the final cellulase solution within the pH range required for optimal cellulase activity. The determination of the optimal pH range of the cellulases of the invention can be ascertained according to well known techniques. Suitable buffers at pH within the activity range of the cellulase are well known to those skilled in the art in the field.

5 In addition to cellulase and a buffer, the treating composition may optionally contain a surfactant. Suitable surfactants include any surfactant compatible with the cellulase and the fabric including, for example, anionic, non-ionic and ampholytic surfactants. Suitable anionic surfactants for use herein include linear or branched alkylbenzenesulfonates; alkyl or alkenyl ether sulfates having linear or branched alkyl groups or alkenyl groups; alkyl or alkenyl
10 sulfates; olefinsulfonates; alkanesulfonates and the like. Suitable counter ions for anionic surfactants include alkali metal ions such as sodium and potassium; alkaline earth metal ions such as calcium and magnesium; ammonium ion; and alkanolamines having 1 to 3 alkanol groups of carbon number 2 or 3. Ampholytic surfactants include quaternary ammonium salt sulfonates, and betaine-type ampholytic surfactants. Such ampholytic surfactants have both
15 the positive and negative charged groups in the same molecule. Nonionic surfactants generally comprise polyoxyalkylene ethers, as well as higher fatty acid alkanolamides or alkylene oxide adduct thereof, and fatty acid glycerine monoesters. Mixtures of surfactants can also be employed in manners known to those skilled in the art.

A concentrated cellulase composition can be prepared for use in the methods
20 described herein. Such concentrates contain concentrated amounts of the cellulase composition described above, buffer and surfactant, preferably in an aqueous solution. When so formulated, the cellulase concentrate can readily be diluted with water so as to quickly and accurately prepare cellulase preparations having the requisite concentration of each constituent. When aqueous concentrates are formulated, these concentrates can be
25 diluted so as to arrive at the requisite concentration of the components in the cellulase solution as indicated above. As is readily apparent, such cellulase concentrates will permit facile formulation of the cellulase solutions as well as permit feasible transportation of the composition to the location where it will be used. The treating concentrate can be in any art recognized form, for example, liquid, emulsion, gel, or paste. Such forms are well known to
30 those skilled in the art.

When a solid cellulase concentrate is employed, the cellulase composition may be a granule, a powder, an agglomerate or a solid disk. The granules can be formulated so as to contain materials to reduce the rate of dissolution of the granules into the wash medium. Such materials and granules are disclosed in U.S. Patent No. 5,254,283 which is
35 incorporated herein by reference in its entirety.

-- 23 --

Other materials can also be used with or placed in the cellulase composition of the present invention as desired, including stones, pumice, fillers, solvents, enzyme activators, and anti-redeposition agents depending on the eventual use of the composition.

By way of example, stonewashing methods will be described in detail, however, the parameters described are readily modified by the skilled artisan for other applications, i.e., improving the feel and/or appearance of a fabric. The cellulose containing fabric is contacted with the cellulase containing stonewashing composition containing an effective amount of the cellulase by intermingling the treating composition with the stonewashing composition, and thus bringing the cellulase enzyme into proximity with the fabric.

Subsequently, the aqueous solution containing the cellulase and the fabric is agitated. If the treating composition is an aqueous solution, the fabric may be directly soaked in the solution. Similarly, where the stonewashing composition is a concentrate, the concentrate is diluted into a water bath with the cellulose containing fabric. When the stonewashing composition is in a solid form, for example a pre-wash gel or solid stick, the stonewashing composition may be contacted by directly applying the composition to the fabric or to the wash liquor.

The cellulose containing fabric is incubated with the stonewashing solution under conditions effective to allow the enzymatic action to confer a stonewashed appearance to the cellulose containing fabric. For example, during stonewashing, the pH, liquor ratio, temperature and reaction time may be adjusted to optimize the conditions under which the stonewashing composition acts. "Effective conditions" necessarily refers to the pH, liquor ratio, and temperature which allow the cellulase enzyme to react efficiently with cellulose containing fabric, in this case to produce the stonewashed effect. However, such conditions are readily ascertainable by one of skill in the art. The reaction conditions effective for the stonewashing compositions of the present invention are substantially similar to well known methods used with corresponding prior art cellulase compositions. Accordingly, it is within the skill of those in the art to maximize conditions for using the stonewashing compositions according to the present invention.

The liquor ratios during stonewashing, i.e., the ratio of weight of stonewashing composition solution (i.e., the wash liquor) to the weight of fabric, employed herein is generally an amount sufficient to achieve the desired stonewashing effect in the denim fabric and is dependent upon the process used. Preferably, the liquor ratios are from about 4:1 to about 50:1; more preferably from about 5:1 to about 20:1, and most preferably from about 10:1 to about 15:1.

Reaction temperatures during stonewashing with the present stonewashing compositions are governed by two competing factors. Firstly, higher temperatures generally

correspond to enhanced reaction kinetics, i.e., faster reactions, which permit reduced reaction times as compared to reaction times required at lower temperatures. Accordingly, reaction temperatures are generally at least about 10°C and greater. Secondly, cellulase is a protein which loses activity beyond a given reaction temperature, which temperature is
5 dependent on the nature of the cellulase used. Thus, if the reaction temperature is permitted to go too high, the cellulolytic activity is lost as a result of the denaturing of the cellulase. While standard temperatures for cellulase usage in the art are generally in the range of 35°C to 65°C, which conditions would also be expected to be suitable for the cellulase of the invention, the optimal temperature conditions should be ascertained according to well known
10 techniques with respect to the specific cellulase used.

Reaction times are dependent on the specific conditions under which the stonewashing occurs. For example, pH, temperature and concentration of cellulase will all effect the optimal reaction time. Generally, reaction times are from about 5 minutes to about 5 hours, and preferably from about 10 minutes to about 3 hours and, more preferably, from
15 about 20 minutes to about 1 hour.

According to yet another preferred embodiment of the present invention, the cellulase of the invention may be employed in a detergent composition. The detergent compositions according to the present invention are useful as pre-wash compositions, pre-soak compositions, or for cleaning during the regular wash or rinse cycle. Preferably, the
20 detergent composition of the present invention comprises an effective amount of cellulase, a surfactant, and optionally includes other ingredients described below.

An effective amount of cellulase employed in the detergent compositions of this invention is an amount sufficient to impart the desirable effects known to be produced by cellulase on cellulose containing fabrics, for example, depilling, softening, anti-pilling, surface
25 fiber removal, anti-graying and cleaning. Preferably, the cellulase in the detergent composition is employed in a concentration of from about 10 ppm to about 20,000 ppm of detergent.

The concentration of cellulase enzyme employed in the detergent composition is preferably selected so that upon dilution into a wash medium, the concentration of cellulase
30 enzyme is in a range of about 0.01 to about 1000 ppm, preferably from about 0.02 ppm to about 500 ppm, and most preferably from about 0.5 ppm to about 250 ppm total protein. The amount of cellulase enzyme employed in the detergent composition will depend on the extent to which the detergent will be diluted upon addition to water so as to form a wash solution.

The detergent compositions of the present invention may be in any art recognized form, for example, as a liquid, in granules, in emulsions, in gels, or in pastes. Such forms are well known to the skilled artisan. When a solid detergent composition is employed, the cellulase is preferably formulated as granules. Preferably, the granules can be formulated so as to additionally contain a cellulase protecting agent. The granule can be formulated so as to contain materials to reduce the rate of dissolution of the granule into the wash medium. Such materials and granules are disclosed in U.S. Patent No. 5,254,283 which is incorporated herein by reference in its entirety.

The detergent compositions of this invention employ a surface active agent, i.e., surfactant, including anionic, non-ionic and ampholytic surfactants well known for their use in detergent compositions.

Suitable anionic surfactants for use in the detergent composition of this invention include linear or branched alkylbenzenesulfonates; alkyl or alkenyl ether sulfates having linear or branched alkyl groups or alkenyl groups; alkyl or alkenyl sulfates; olefinsulfonates; and alkanesulfonates. Suitable counter ions for anionic surfactants include alkali metal ions such as sodium and potassium; alkaline earth metal ions such as calcium and magnesium; ammonium ion; and alkanolamines having 1 to 3 alkanol groups of carbon number 2 or 3. Ampholytic surfactants include quaternary ammonium salt sulfonates, and betaine-type ampholytic surfactants. Such ampholytic surfactants have both the positive and negative charged groups in the same molecule. Nonionic surfactants generally comprise polyoxyalkylene ethers, as well as higher fatty acid alkanolamides or alkylene oxide adduct thereof, fatty acid glycerine monoesters, and the like. Suitable surfactants for use in this invention are disclosed in British Patent Application No. 2 094 826 A, the disclosure of which is incorporated herein by reference. Mixtures of such surfactants can also be used. The surfactant or a mixture of surfactants is generally employed in the detergent compositions of this invention in an amount from about 1 weight percent to about 95 weight percent of the total detergent composition and preferably from about 5 weight percent to about 45 weight percent of the total detergent composition. In addition to the cellulase composition and the surfactant(s), the detergent compositions of this invention can optionally contain one or more of the following components:

Hydrolases Except Cellulase

Suitable hydrolases include carboxylate ester hydrolase, thioester hydrolase, phosphate monoester hydrolase, and phosphate diester hydrolase which act on the ester bond; glycoside hydrolase which acts on glycosyl compounds; an enzyme that hydrolyzes N-

glycosyl compounds; thioether hydrolase which acts on the ether bond; and α -amino-acyl-peptide hydrolase, peptidyl-amino acid hydrolase, acyl-amino acid hydrolase, dipeptide hydrolase, and peptidyl-peptide hydrolase which act on the peptide bond. Preferable among them are carboxylate ester hydrolase, glycoside hydrolase, and peptidyl-peptide hydrolase.

- 5 Suitable hydrolases include (1) proteases belonging to peptidyl-peptide hydrolase such as pepsin, pepsin B, rennin, trypsin, chymotrypsin A, chymotrypsin B, elastase, enterokinase, cathepsin C, papain, chymopapain, ficin, thrombin, fibrinolysin, renin, subtilisin, aspergillopeptidase A, collagenase, clostridiopeptidase B, kallikrein, gastrisin, cathepsin D., bromelin, keratinase, chymotrypsin C, pepsin C, aspergillopeptidase B, urokinase,
- 10 carboxypeptidase A and B, and aminopeptidase; (2) glycoside hydrolases (cellulase which is an essential ingredient is excluded from this group) α -amylase, β -amylase, gluco amylase, invertase, lysozyme, pectinase, chitinase, and dextranase. Preferably among them are α -amylase and β -amylase. They function in acid to neutral systems, but one which is obtained from bacteria exhibits high activity in an alkaline system; (3) carboxylate ester hydrolase
- 15 including carboxyl esterase, lipase, pectin esterase, and chlorophyllase. Especially effective among them is lipase.

The hydrolase other than cellulase is incorporated into the detergent composition as much as required according to the purpose. It should preferably be incorporated in an amount of 0.001 to 5 weight percent, and more preferably 0.02 to 3 weight percent, in terms

20 of purified protein. This enzyme should be used in the form of granules made of crude enzyme alone or in combination with other components in the detergent composition. Granules of crude enzyme are used in such an amount that the purified enzyme is 0.001 to 50 weight percent in the granules. The granules are used in an amount of 0.002 to 20 and preferably 0.1 to 10 weight percent. As with cellulases, these granules can be formulated so

25 as to contain an enzyme protecting agent and a dissolution retardant material.

Cationic Surfactants and Long-Chain Fatty Acid Salts

Such cationic surfactants and long-chain fatty acid salts include saturated or unsaturated fatty acid salts, alkyl or alkenyl ether carboxylic acid salts, α -sulfofatty acid salts

30 or esters, amino acid-type surfactants, phosphate ester surfactants, quaternary ammonium salts including those having 3 to 4 alkyl substituents and up to 1 phenyl substituted alkyl substituents. Suitable cationic surfactants and long-chain fatty acid salts are disclosed in British Patent Application No. 2 094 826 A, the disclosure of which is incorporated herein by reference. The composition may contain from about 1 to about 20 weight percent of such

35 cationic surfactants and long-chain fatty acid salts.

Builders

A. Divalent sequestering agents.

The composition may contain from about 0 to about 50 weight percent of one or more builder components selected from the group consisting of alkali metal salts and alkanolamine salts of the following compounds: phosphates, phosphonates, phosphonocarboxylates, salts of amino acids, aminopolyacetates high molecular electrolytes, non-dissociating polymers, salts of dicarboxylic acids, and aluminosilicate salts. Suitable divalent sequestering agents are disclosed in British Patent Application No. 2 094 826 A, the disclosure of which is incorporated herein by reference.

B. Alkalis or inorganic electrolytes

The composition may contain from about 1 to about 50 weight percent, preferably from about 5 to about 30 weight percent, based on the composition of one or more alkali metal salts of the following compounds as the alkalis or inorganic electrolytes: silicates, carbonates and sulfates as well as organic alkalis such as triethanolamine, diethanolamine, monoethanolamine and triisopropanolamine.

Antiredeposition Agents

The composition may contain from about 0.1 to about 5 weight percent of one or more of the following compounds as antiredeposition agents: polyethylene glycol, polyvinyl alcohol, polyvinylpyrrolidone and carboxymethylcellulose.

Among them, a combination of carboxymethyl-cellulose and/or polyethylene glycol with the cellulase composition of the present invention provides for an especially useful dirt removing composition.

Bleaching Agents

The use of the cellulase of the present invention in combination with a bleaching agent such as potassium monopersulfate, sodium percarbonate, sodium perborate, sodium sulfate/hydrogen peroxide adduct and sodium chloride/hydrogen peroxide adduct or/and a photo-sensitive bleaching dye such as zinc or aluminum salt of sulfonated phthalocyanine further improves the detergenting effects. Similarly, bleaching agents and bleach catalysts as described in EP 684 304 may be used.

Bluing Agents and Fluorescent Dyes

Various bluing agents and fluorescent dyes may be incorporated in the composition, if necessary. Suitable bluing agents and fluorescent dyes are disclosed in British Patent Application No. 2 094 826 A, the disclosure of which is incorporated herein by reference.

5

Caking Inhibitors

The following caking inhibitors may be incorporated in the powdery detergent: p-toluenesulfonic acid salts, xylenesulfonic acid salts, acetic acid salts, sulfosuccinic acid salts, talc, finely pulverized silica, amorphous silicas, clay, calcium silicate (such as Micro-Cell of Johns Manville Co.), calcium carbonate and magnesium oxide.

10

Masking Agents for Factors Inhibiting the Cellulase Activity

The cellulase composition of this invention are deactivated in some cases in the presence of copper, zinc, chromium, mercury, lead, manganese or silver ions or their compounds. Various metal chelating agents and metal-precipitating agents are effective against these inhibitors. They include, for example, divalent metal ion sequestering agents as listed in the above item with reference to optional additives as well as magnesium silicate and magnesium sulfate.

15

Cellobiose, glucose and gluconolactone act sometimes as inhibitors. It is preferred to avoid the co-presence of these saccharides with the cellulase as far as possible. In case the co-presence is unavoidable, it is necessary to avoid the direct contact of the saccharides with the cellulase by, for example, coating them.

20

Long-chain-fatty acid salts and cationic surfactants act as the inhibitors in some cases. However, the co-presence of these substances with the cellulase is allowable if the direct contact of them is prevented by some means such as tableting or coating.

25

The above-mentioned masking agents and methods may be employed, if necessary, in the present invention.

Cellulase-Activators

The activators may vary depending on the specific cellulase. In the presence of proteins, cobalt and its salts, magnesium and its salts, and calcium and its salts, potassium and its salts, sodium and its salts or monosaccharides such as mannose and xylose, many cellulases are activated and their deterging powers are improved remarkably.

30

-- 29 --

Antioxidants

The antioxidants include, for example, tert-butyl-hydroxytoluene, 4,4'-butylidenebis(6-tert-butyl-3-methylphenol), 2,2'-butylidenebis(6-tert-butyl-4-methylphenol), monostyrenated cresol, distyrenated cresol, monostyrenated phenol, distyrenated phenol and 1,1-bis(4-hydroxy-phenyl)cyclohexane.

Solubilizers

The solubilizers include, for example, lower alcohols such as ethanol, benzenesulfonate salts, lower alkylbenzenesulfonate salts such as p-toluenesulfonate salts, glycols such as propylene glycol, acetylbenzene-sulfonate salts, acetamides, pyridinedicarboxylic acid amides, benzoate salts and urea.

The detergent composition of the present invention can be used in a broad pH range from acidic to alkaline pH. In a preferred embodiment, the detergent composition of the present invention can be used in mildly acidic, neutral or alkaline detergent wash media having a pH of from above 5 to no more than about 12.

Aside from the above ingredients, perfumes, buffers, preservatives, dyes and the like can be used, if desired, with the detergent compositions of this invention. Such components are conventionally employed in amounts heretofore used in the art.

When a detergent base used in the present invention is in the form of a powder, it may be one which is prepared by any known preparation methods including a spray-drying method and a granulation method. The detergent base obtained particularly by the spray-drying method, agglomeration method, dry mixing method or non-tower route methods are preferred. The detergent base obtained by the spray-drying method is not restricted with respect to preparation conditions. The detergent base obtained by the spray-drying method is hollow granules which are obtained by spraying an aqueous slurry of heat-resistant ingredients, such as surface active agents and builders, into a hot space. After the spray-drying, perfumes, enzymes, bleaching agents, inorganic alkaline builders may be added. With a highly dense, granular detergent base obtained such as by the spray-drying-granulation or agglomeration method, various ingredients may also be added after the preparation of the base.

When the detergent base is a liquid, it may be either a homogeneous solution or an inhomogeneous dispersion. For removing the decomposition of carboxymethylcellulose by the cellulase in the detergent, it is desirable that carboxymethylcellulose is granulated or coated before the incorporation in the composition.

-- 30 --

The detergent compositions of this invention may be incubated with cellulose containing fabric, for example soiled fabrics, in industrial and household uses at temperatures, reaction times and liquor ratios conventionally employed in these environments. The incubation conditions, i.e., the conditions effective for treating cellulose
5 containing fabrics with detergent compositions according to the present invention, will be readily ascertainable by those of skill in the art. Accordingly, the appropriate conditions effective for treatment with the present detergents will correspond to those using similar detergent compositions which include known cellulases.

Detergents according to the present invention may additionally be formulated as a
10 pre-wash in the appropriate solution at an intermediate pH where sufficient activity exists to provide desired improvements softening, depilling, pilling prevention, surface fiber removal or cleaning. When the detergent composition is a pre-soak (e.g., pre-wash or pre-treatment) composition, either as a liquid, spray, gel or paste composition, the cellulase enzyme is generally employed from about 0.0001 to about 1 weight percent based on the total weight of
15 the pre-soak or pre-treatment composition. In such compositions, a surfactant may optionally be employed and when employed, is generally present at a concentration of from about 0.005 to about 20 weight percent based on the total weight of the pre-soak. The remainder of the composition comprises conventional components used in the pre-soak, i.e., diluent, buffers, other enzymes (proteases), and the like at their conventional concentrations.

20 It is contemplated that compositions comprising cellulase enzymes described herein can be used in home use as a stand alone composition suitable for restoring color to faded fabrics (see, for example, U.S. Patent No. 4,738,682, which is incorporated herein by reference in its entirety) as well as used in a spot-remover and for depilling and antipilling (pilling prevention).

25 The use of the cellulase according to the invention may be particularly effective in feed additives and in the processing of pulp and paper. These additional industrial applications are described in, for example, PCT Publication No. 95/16360 and Finnish Granted Patent No. 87372, respectively.

In order to further illustrate the present invention and advantages thereof, the
30 following specific examples are given with the understanding that they are being offered to illustrate the present invention and should not be construed in any way as limiting its scope.

-- 31 --

EXAMPLE

Genomic DNA was prepared for several different microorganisms for the purpose of undertaking a PCR reaction to determine whether EGIII like enzymes are encoded by the DNA for a particular organism.

5 Genomic DNA is obtained from *Acremonium brachyphenium* deposit no. CBS 866.73; *Chaetomium brasiliense* deposit no. CBS 140.50; *Chaetomium vitellium* deposit no. CBS 250.85; *Emmericella desertoru* deposit no. CBS 653.73; *Fusarium equiseti* deposit no. CBS 185.34; *Glilocladium roseum* deposit no. CBS 443.65; *Humicola grisea* var. *thermoidia* deposit no. CBS 225.63; *Myceliophthora thermophila* deposit no. ATCC 48102-48104; 10 *Penicillium notatum* deposit no. ATCC 9178, 9179; and *Phanerochaete chrysosporium* deposit no. ATCC 28326 and isolated according to standard methods.

PCR was performed on a standard PCR machine such as the PCT-150 MicroCycler from MJ Research Inc. under the following conditions:

- 1) 1 minute at 98°C for 1 cycle;
- 15 2) 1 minute at 94°C,
90 seconds at 40°C,
1 minute at 72°C
- 3) repeat step 2 for 30 cycles
- 4) 7 minutes at 72°C for 1 cycle
- 20 5) lower temperature to 15°C for storage and further analysis.

The following DNA primers were constructed for use in amplification of EGIII like genes from the libraries constructed from the various microorganisms. All symbols used herein for protein and DNA sequences correspond to IUPAC IUB Biochemical Nomenclature 25 Commission codes.

BOX1: primers coding for (N/Q)NLWG

forward primer FRG001: AAY AAY YTN TGG GG

forward primer FRG002: CAR AAY YTN TGG GG

30 BOX1': primers coding for NNN(F/L/Y/I/L/N/K)WG

forward primer FRG010: AAY AAY AAY HWI TGG GG

BOX2: primers coding for ELMIW

35 forward primer FRG003: GAR YTN ATG ATH TGG

-- 32 --

reversed primer FRG004: CCA DAT CAT NAR YTC

BOX2': primers coding for YELMIW

forward primer FRG011: TAY GAR YTI ATG ATH TGG

5 reversed primer FRG012: CCA DAT CAT IAR YTC RTA

BOX3: primers coding for GTE(P/C)FT

reversed primer FRG005: GTR AAN GGY TCR GTR CC

reversed primer FRG006: GTR AAN GGY TCR GTY CC

10 reversed primer FRG007: GTR AAN GGY TCY GTR CC

reversed primer FRG008: GTR AAN GGY TCY GTY CC

reversed primer FRG009: GTR AAR CAY TCN GTN CC

PCR conditions for PWO polymerase (Boehringer Mannheim, Cat # 1644-947)

15 comprise a 100 microliter solution made of 10 microliter of 10X reaction buffer (10X reaction buffer comprising 100mM Tris HCl, pH 8-8.5; 250 mM KCl; 50 mM (NH₄)₂SO₄; 20 mM MgSO₄); 0.2 mM each of dATP, dTTP, dGTP, dCTP (final concentration), 1 microliter of 100 nanogram/microliter genomic DNA, 1 microliter of PWO at 1 unit per microliter, 500 mM primers (final concentration) and water to 100 microliters. The solution is overlaid with
20 mineral oil.

The PCR strategy was as follows: forward primers for BOX1 and BOX1' were combined with reversed primers from BOX3 in a mixture with the desired genomic DNA sample and run on a gel to obtain fragments in the 400-1000 base pair range. The obtained fragments were then pooled and the pool split into two approximately equal portions. The
25 first pool was combined with the forward primers from BOX1 and BOX1' along with the reversed primer from BOX2. The second pool was combined with the forward primer from BOX2 along with the reversed primers from BOX3. Fragments having the approximate size relative to an EGIII like cellulase considering the location of the primers within the gene, in this case corresponding to those between 250-500 base pairs, were isolated and sequenced.
30 Partial sequences for EGIII like cellulase genes are provided in Fig. 3.

The isolated and partially sequenced DNA and the corresponding amino acid sequences (of approximately 100 residues) were analyzed to determine their relationship to EGIII. The results of this sequence alignment are shown in Fig. 3. As shown in Fig. 3, significant sequence homology exists between the peptides encoded by the obtained DNA
35 fragments and corresponding peptide sequences from EGIII. Due to this homology, it was

-- 33 --

concluded by Applicants that the nature of the numerous conserved residues identify the fragment as corresponding to a gene encoding a cellulase. Moreover, the high homology and strong conservation of residues corresponding to peptides (a), (b), (c) and/or (d), as in EGIII, identify the genes as coding an EGIII like enzyme from each of the organisms. Fig. 4 illustrates the percent similarity of the protein fragments sequenced.

From the sequenced fragments, it was possible to use the RAGE technique (rapid amplification of genomic ends) to rapidly obtain the sequence of the full length gene. Full length genes were obtained and are provided with several additional EGIII-like cellulase sequences in Fig. 6. As shown in Fig. 6, full length genes isolated from *Hypocrea schweinitzii*, *Aspergillus aculeatus*, *Aspergillus kawachii* (1), *Aspergillus kawachii* (2), *Aspergillus oryzae*, *Humicola grisea*, *Humicola insolens*, *Chaetomium brasiliense*, *Fusarium equiseti*, *Fusarium javanicum* (1), *Fusarium javanicum* (2), *Gliocladium roseum* (1), *Gliocladium roseum* (2), *Gliocladium roseum* (3), *Gliocladium roseum* (4), *Memnoniella echinata*, *Actinomyces* 11AG8, *Streptomyces lividans* CelB, *Rhodothermus marinus*, *Emericella desertoru*, and *Erwinia carotovora* all comprise significant homology EGIII from *Trichoderma reesei*.

-- 34 --

CLAIMS

1. An enzyme comprising cellulolytic activity comprising an amino acid sequence comprising an amino acid string selected from the group consisting of one or more of the following:
 - (a) Asn-Asn-(Leu/Phe/Lys/Ile)-Trp-Gly
 - (b) Glu-(Leu/Phe/Ile)-Met-Ile-Trp
 - (c) Gly-Thr-Glu-Pro-Phe-Thr;
 - (d) (Ser/Tyr/Cys/Trp/Thr/Asn/Lys/Arg)-(Val/Pro)-(Lys/Ala)-(Ser/Ala)-(Tyr/Phe); and
 - (e) Lys-Asn-Phe-Phe-Asn-Tyror a derivative of said enzyme.
2. The enzyme according to claim 1, said cellulase being derived from a fungus, bacteria or Actinomycete.
3. The enzyme according to claim 1, wherein said enzyme is an endoglucanase.
4. The enzyme according to claim 2, wherein said fungus is a filamentous fungus.
5. The enzyme according to claim 4, wherein said filamentous fungus belongs to Euscomycete.
6. The enzyme according to claim 5, wherein said Euscomycete belongs to Plectomycete.
7. The enzyme according to claim 5, wherein said Euscomycete belongs to Diaporthales, Halosphaeriales, Microascales, Ophiostomatales, Phyllachorales, Sordariales or Xylariales.
8. The enzyme according to claim 5, wherein said Euscomycete belongs to Hypocreales comprising Clavicipitaceae, Melanosporaceae, Nectriaceae, Niessliaceae or Mitosporic Hypocreales.

-- 35 --

9. The enzyme according to claim 5, wherein said Euascomycete belongs to Hypocreaceae, wherein said Hypocreaceae does not comprise Trichoderma.

10. The enzyme according to claim 5, wherein said Euascomycete is *Gliocladium* spp., *Fusarium* spp., *Acremonium* spp., *Myceliophthora* spp., *Verticillium* spp., *Myrothecium* spp., or *Penicillium* spp.

11. The enzyme according to claim 5, wherein said Euascomycete is an *Aspergillus* comprising *A. aeneus*, *A. anthodesmis*, *A. aureofulgens*, *A. aureolatus*, *A. avenaceus*, *A. awamori*, *A. bisporus*, *A. brunneouniseriatus*, *A. campestris*, *A. caesiellus*, *A. candidus*, *A. carbonarius*, *A. carneus*, *A. cervinus*, *A. clavatoflavus*, *A. clavatoanicus*, *A. clavatus*, *A. conicus*, *A. conjunctus*, *A. crustosus*, *A. deflectus*, *A. dimorphicus*, *A. eburneocreus*, *A. egyptiacus*, *A. ellipticus*, *A. elongatus*, *A. ficuum*, *A. flaschentraegeri*, *A. flavus*, *A. fumigatus*, *A. giganteus*, *A. glaucus*, *A. gorakhpurensis*, *A. gracilis*, *A. iizuke*, *A. itaconicus*, *A. japonicus*, *A. kambarensis*, *A. kanagawaensis*, *A. lanosus*, *A. leporis*, *A. longivesica*, *A. mellinus*, *A. multicolor*, *A. niger*, *A. nomius*, *A. nutans*, *A. ochraceus*, *A. oryzae*, *A. pallidus*, *A. panamensis*, *A. parasiticus*, *A. parvulus*, *A. penicillioides*, *A. phialisepticus*, *A. phoenicis*, *A. proliferans*, *A. pulvinus*, *A. puniceus*, *A. raperi*, *A. recurvatus*, *A. restrictus*, *A. shirousami*, *A. sojae*, *A. sparsus*, *A. subolivaceus*, *A. subsessilis*, *A. tamarii*, *A. terreus*, *A. terricola*, *A. thomii*, *A. tubingensis*, *A. unguis*, *A. unilateralis*, *A. ustus*, *A. versicolor*, *A. wentii*, *A. xerophilus*, *A. zonatus*, *A. sp.*

12. The enzyme according to claim 1, wherein said enzyme has an amino acid sequence identity with that of EGIII of greater than 30%.

13. The enzyme according to claim 12, wherein said enzyme has an amino acid sequence identity with that of EGIII of greater than 60%.

14. A DNA encoding the enzyme according to claim 1.

15. A vector comprising the DNA of claim 14.

16. A host cell transformed with the vector of claim 15.

-- 36 --

17. A method of producing a cellulase comprising the steps of:
- (a) culturing the host cell according to claim 16 in a suitable culture medium under suitable conditions to produce cellulase;
 - (b) obtaining said produced cellulase; and optionally
 - (c) purifying said cellulase to provide a purified cellulase product.
18. A method for obtaining a gene encoding an EGIII like cellulase comprising the steps of
- (a) preparing genomic DNA from an organism of interest;
 - (b) preparing a DNA primer encoding an amino acid string selected from the group consisting of one or more of the following:
 - (a) Asn-Asn-(Leu/Phe/Lys/Ile)-Trp-Gly
 - (b) Glu-(Leu/Phe/Ile)-Met-Ile-Trp
 - (c) Gly-Thr-Glu-Pro-Phe-Thr;
 - (d) (Ser/Tyr/Cys/Trp/Thr/Asn/Lys/Arg)-(Val/Pro)-(Lys/Ala)-(Ser/Ala)-(Tyr/Phe); and
 - (e) Lys-Asn-Phe-Phe-Asn-Tyr.
 - (c) mixing said genomic DNA from step (a) and said DNA primer from step (b) under conditions suitable for the identification of all or part of a gene fragment in said genomic DNA corresponding to said DNA primer; and
 - (d) isolating said all or part of said gene corresponding to said fragment from said genomic DNA.
19. The method according to claim 18, wherein said step (c) further comprises labeling said DNA primer and performing hybridization between said labeled DNA primer and said genomic DNA and detecting said hybridized genomic DNA which encodes all or part of an EGIII like cellulase.

-- 37 --

20. The method according to claim 18, wherein, said step (c) further comprises initiating a PCR reaction between said DNA primer and said genomic DNA and identifying a resulting amplified DNA fragment which comprises all or part of a gene encoding an EGIII like cellulase.

21. The method according to claim 18, wherein said genomic DNA is obtained from a bacteria, fungus or Actinomycete.

22. A vector comprising the gene isolated according to claim 18.

23. A host cell transformed with the vector of claim 22.

24. An EGIII like cellulase encoded by the gene obtained according to claim 18.

25. The use of the EGIII like cellulase according to claim 24 in the treatment of a cellulose containing textile.

26. The use of the EGIII like cellulase according to claim 24 as a feed additive.

27. The use of the EGIII like cellulase according to claim 24 in the treatment of wood pulp.

28. The use of the EGIII like cellulase according to claim 24 in the reduction of biomass to glucose. The use of the EGIII like cellulase according to claim 24 in the stonewashing or indigo dyed denim.

29. A laundry detergent comprising the EGIII like cellulase according to claim 24.

~~1/5~~

1/8

09/284327

Amino Acid Sequence of EGIII

MKFLQVLPALIPAALAQTSCDQWATFTGNGYTVSNNLWGASAGSGFGCVTAVSLSGGAHADW
QWSGGQNNVKSQNSQIAIPQKRTVNSISSMPTTASWSYSGSNIRANVAYDLFTAANPNHVT
YSGDYELMIWLKGKYGDIGPIGSSQGTNVNQGQSWTLYYGYNGAMQVYSFVAQTNTTNYSGDV
KNFFNYLRDNKGYNAAAGQYVLSYQFGTEPFTGSGTLNVA SWTASIN

FIGURE 1



- Unidentified

3/5

3/8

09/284327

	NNLWGKDSG--GSQCTTVDSLSDGGI-SWSTAWSWSGGEGNVKSYPNS-----GLQFSAGKK-VSSISS										
	10	20	30	40	50	60	70				
EG3IN.PRO	NNLWGASAGS-GFGCVTAVSLSG-GA-SWHADWQWSGGQNNVKSYPNS-----	QIAIPQ-KRTVNSISS	60								
FUSEQIN.PRO	NNFWGKDSGT-GDQCTHVNNNANGA-GWDVEWNWSGGKDNVKSYPNS-----	ALLIGEDKKTISSITN	62								
GLIOIN.PRO	NNKWGGQSGS-GSQCLTIDKTWDSNV-AFHADWSWSGGTNNVKSYPKR-----	RSEFSRGKK-VSSIGT	61								
ACRHYPO.PRO	---WGPRSAESGEQCTTNNGLSDDGTLWSVETWVGAPSSVKSYPN-----	VFVEAEPRPLSEVSS	59								
ASPKAWA1.PRO	QNLWGEYQGT-GSQCVYVDKLSSSGA-SWHTKWTWSGGEGTVKSYSNS-----	GLTF-D-KKLVSQISQ	60								
ASPACU1.PRO	NNLWGKDAGS-GSQCTTVNSASSAGT-SWSTKWNWSGGGENSVKSYSANS-----	GLTF-N-KKLVSQISQ	60								
HUMIN.PRO	NNLWGKDTATSGWQCTYLDGTNNGGI-QWSTAWEWQGAPDNVKSYPYV-----	GKQIQRGRK-ISDINS	62								
11AG8IN.PRO	NNRWGTSAT----QC----INVTGNGFEITQADGSVPTNGAPKSYPSVYDCHYGNC-APRTTLPMRISS	61									
ERWCARIN.PRO	NNVWGKDEI----KG-WQQTIFYNSPISMGWNWHWPSSTHSVKAYPSLVSGWHWTAGYTENSGLPQLSS	65									
GLIO314.PRO	NNLWGMGSGS-GSQCTYVDKVAEGV-AWHTDWSWSGGDNVKSYPYS-----	GRELGTKRI-VSSIKS	61								
GLIO3HYP.PRO	NNLWGDQNG-SGSQCLTVEGVTDGLA-AWSSTWSWSGGSSSVKSYSNA-----	VLSAEAR--ISAISS	60								
HGRIS.PRO	NNLWQDTSATSGWQCTYLDGTNNGGI-QWSTAWEWQGAPDNVKSYPYV-----	GKQIQRGRK-ISDINS	62								
RHMARIN.PRO	NNVWGAETA----QC--IEVGLETGNFTITRADH--DNGNNVAAYPATYFGCHWAPARAIKCAARAGAV	62									
SLIVIN.PRO	NNRWGSTAP----QC----VTATDTGFRVTQADGSAPTNGAPKSYPSVFNGCHYTNC-SPGTDLPVRLDT	61									
PENNOT.PRO	---WGKDSGS-GSQCASVNSISDSGV-SWSTWNNWSGGEDNVKSYPNS-----	GLVALK-KQPVSDISS	58								
PHANHYPO.PRO	---WGKDSG-TGSQCLTVDGISSGLL-KWSATWSWSGGPYNVKSYPNA-----	VLQAPAAAR--ASAISS	57								
F42HYPO.PRO	-----S-----QCTTFESLSGNTI-VWNTKWSWSGGQGVKSIFANA-----	ALQFTPKK--LSSVKS	49								
EMDESHYP.PRO	NNLWGXDNDADSGSQCTGVDSANGNSI-SWHTTWSWSGGSSSVKSYSANA-----	AYQFTSTK--LNSLSS	61								
MYCINS.PRO	-----	1									
CHBRAS.PRO	NNFWGQSRATSGSQCTYLDSSNSGI-HWHTIWTWEGGEGEVKSYAYS-----	GRQVSTGLT-IASIDS	62								

	IPSSASWV-YSGTDIRA-NVAYDL-FTAADPNHATSSGDYELMIW				
	80	90	100	110	
EG3IN.PRO	MPTTASWS-YSGSNIRA-NVAYDL-FTAANPNHVTYSGDYELMIW				102
FUSEQIN.PRO	MQSTAWEK-YSGDNLRA-DVAYDL-FTAADPNHETSSGEYELMIW				104
GLIOIN.PRO	INGGADWD-YSGSNIRA-NVAYGI-FTSADPNHVTSSGDYELMIW				103
ACRHYPO.PRO	IQAEWAWTYSGAGDFTT-NVAFDI-FTGETAD				89
ASPKAWA1.PRO	IPTSVTWS-QDDTNVQA-DVSYDL-FTAANADHATSSGDYELMIW				102
ASPACU1.PRO	IPTTARWS-YDNTGIRA-DVAYDL-FTAADINHVTWSGDYELMIW				102
HUMIN.PRO	MRTSVSWT-YDRTDIRA-NVAYDV-FTARDPDHPNWGGDYELMIW				104
11AG8IN.PRO	IGSAPSSVSRYRTGNGVYNAAYDIWLDPTPRINGVNR--TEIMIW				104
ERWCARIN.PRO	NKSITSNVTYSIKATGTYNAAAYDIWFHTTIDKANWDSSTDELMIW				110
GLIO314.PRO	ISSGADWD-YTGSNLRA-NAAYDI-FTSANPNHATSSGDYELMIW				103
GLIO3HYP.PRO	IPSKWEWRSYTGTDIVA-NVAYDL-FSNTDCGDTP---EYELMIW				100
HGRIS.PRO	MRTSVSWT-YDRTDIRA-NVAYDV-FTARDPDHPNWGGDYEFMIW				104
RHMARIN.PRO	RAHELDVT-PI-TTGRWNAAYDIWFSPVTNSGNGYSGGAELMIW				105
SLIVIN.PRO	VSAAPSSISYGFVDGAVYNASYDIWLDPTARTDGVNQ--TEIMIW				104
PENNOT.PRO	IPSSVKWN-YDNTDIRA-DVAYDL-FTAADINHDTSSGDYE				96
PHANHYPO.PRO	IPSKWQWESYTGSNVIA-NVAYDL-FSNSDCG				87
F42HYPO.PRO	IDSTWKWSYSGSNIVA-DVAYDM-FLSTSPGGDH---NY				84
EMDESHYP.PRO	IPTSWKWQ-YSTTDIVA-NVAYDL-FTSSSAGGDS---EYEFMIW				100
MYCINS.PRO	-----A-NVAYDL-FTAADPNHATSSGDYELMIW				27
CHBRAS.PRO	MQTSVSWE-YNTTDIQA-NVAYDI-FTAEDPDHEHSSGDYELMIW				104

FIGURE 3

09/284327

		Percent Similarity																					
	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20			
1		51.0	52.9	27.0	49.0	56.9	43.1	17.6	18.6	55.9	37.0	42.2	16.7	14.7	50.0	39.1	36.9	36.0	88.9	46.1	1		
2	43.1		48.5	22.5	47.1	55.9	43.3	15.4	21.2	54.4	37.0	41.3	15.4	13.5	55.2	40.2	34.5	34.0	88.9	42.3	2		
3	42.6	48.5		21.3	42.2	49.0	41.7	15.5	22.3	68.9	38.0	41.7	16.5	12.6	50.0	40.2	34.5	33.0	85.2	44.7	3		
4	66.7	66.3	70.6		25.8	31.5	31.5	18.0	20.2	22.5	34.8	31.5	12.4	16.9	28.1	33.3	28.6	33.7	22.2	29.2	4		
5	44.6	51.0	53.5	63.1		65.7	40.2	12.7	22.5	51.0	38.0	39.2	11.8	12.7	59.4	41.4	36.9	40.0	81.5	49.0	5		
6	36.6	41.2	46.5	61.9	34.3		46.1	16.7	24.5	52.0	46.0	44.1	13.7	15.7	69.8	44.8	41.7	47.0	85.2	47.1	6		
7	54.5	50.5	56.3	60.5	52.5	48.5		21.2	19.2	45.6	34.0	98.1	19.2	14.4	49.0	35.6	28.6	41.0	74.1	61.5	7		
8	75.0	77.7	76.3	80.0	77.2	72.8	71.0		24.0	19.4	21.0	21.2	24.0	66.3	14.6	16.1	14.3	20.0	22.2	18.3	8		
9	73.5	71.0	73.7	78.6	77.6	71.4	73.7	68.3		22.3	19.0	17.3	23.8	21.2	20.8	16.1	16.7	20.0	37.0	22.1	9		
10	42.6	43.7	31.1	68.2	46.5	45.5	52.4	72.0	72.7		40.0	44.7	17.5	14.6	55.2	41.4	34.5	37.0	85.2	49.5	10		
11	55.2	53.1	55.1	58.8	55.2	47.9	54.5	70.3	71.9	53.1		34.0	16.0	16.0	41.7	72.4	45.2	50.0	44.4	33.0	11		
12	55.4	52.4	56.3	60.5	53.5	50.5	1.9	71.0	75.8	53.4	54.5		18.3	14.4	47.9	34.5	28.6	42.0	70.4	61.5	12		
13	73.1	75.8	74.5	79.7	80.6	77.4	72.3	67.0	69.5	72.3	76.9	73.4		21.2	11.5	12.6	10.7	14.0	33.3	15.4	13		
14	80.4	81.9	76.3	81.2	81.5	80.4	74.2	33.7	73.1	77.4	76.9	74.2	72.0		13.5	13.8	14.3	15.0	22.2	15.4	14		
15	46.3	41.7	48.4	60.0	37.9	27.4	48.4	76.7	73.9	45.3	47.8	49.5	81.6	84.9		47.1	35.7	40.6	74.1	50.0	15		
16	54.2	54.1	54.1	61.2	55.4	50.6	57.0	74.7	74.7	51.8	27.6	58.1	79.5	83.5	44.0		44.0	41.4	33.3	31.0	16		
17	55.6	56.6	61.4	67.5	59.3	55.6	68.7	80.8	81.9	59.0	56.0	68.7	87.2	83.3	58.5	54.4		56.0	25.9	35.7	17		
18	51.0	56.1	58.2	59.5	51.0	45.8	53.5	75.3	69.1	56.1	42.9	52.5	77.5	78.7	48.9	51.8	40.2		44.4	46.0	18		
19	11.1	11.1	14.8	57.1	18.5	14.8	25.9	68.0	51.9	14.8	37.5	29.6	55.6	72.0	13.0	35.7	57.9	41.7		81.5	19		
20	50.5	52.4	53.4	61.6	45.5	49.5	38.5	71.0	73.7	48.5	57.6	38.5	75.5	74.2	48.4	62.8	61.4	48.5	18.5		20		
	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20			

		Percent Divergence																					
	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20			

FIGURE 4

Percent Divergence

5/12

RQ/US 29 JAN 1992

09/284327

	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	
1		51.0	52.9	27.0	49.0	56.9	43.1	17.6	18.6	55.9	37.0	42.2	16.7	14.7	50.0	39.1	36.9	36.0	88.9	46.1	1
2	43.1		48.5	22.5	47.1	55.9	43.3	15.4	21.2	54.4	37.0	41.3	15.4	13.5	55.2	40.2	34.5	34.0	88.9	42.3	2
3	42.6	48.5		21.3	42.2	49.0	41.7	15.5	22.3	68.9	38.0	41.7	16.5	12.6	50.0	40.2	34.5	33.0	85.2	44.7	3
4	66.7	66.3	70.6		25.8	31.5	31.5	18.0	20.2	22.5	34.8	31.5	12.4	16.9	28.1	33.3	28.6	33.7	22.2	29.2	4
5	44.6	51.0	53.5	63.1		65.7	40.2	12.7	22.5	51.0	38.0	39.2	11.8	12.7	59.4	41.4	36.9	40.0	81.5	49.0	5
6	36.6	41.2	46.5	61.9	34.3		46.1	16.7	24.5	52.0	46.0	44.1	13.7	15.7	69.8	44.8	41.7	47.0	85.2	47.1	6
7	54.5	50.5	56.3	60.5	52.5	48.5		21.2	19.2	45.6	34.0	98.1	19.2	14.4	49.0	35.6	28.6	41.0	74.1	61.5	7
8	75.0	77.7	76.3	80.0	77.2	72.8	71.0		24.0	19.4	21.0	21.2	24.0	66.3	14.6	16.1	14.3	20.0	22.2	18.3	8
9	73.5	71.0	73.7	78.6	77.6	71.4	73.7	68.3		22.3	19.0	17.3	23.8	21.2	20.8	16.1	16.7	20.0	37.0	22.1	9
10	42.6	43.7	31.1	68.2	46.5	45.5	52.4	72.0	72.7		40.0	44.7	17.5	14.6	55.2	41.4	34.5	37.0	85.2	49.5	10
11	55.2	53.1	55.1	58.8	55.2	47.9	54.5	70.3	71.9	53.1		34.0	16.0	16.0	41.7	72.4	45.2	50.0	44.4	33.0	11
12	55.4	52.4	56.3	60.5	53.5	50.5	1.9	71.0	75.8	53.4	54.5		18.3	14.4	47.9	34.5	28.6	42.0	70.4	61.5	12
13	73.1	75.8	74.5	79.7	80.6	77.4	72.3	67.0	69.5	72.3	76.9	73.4		21.2	11.5	12.6	10.7	14.0	33.3	15.4	13
14	80.4	81.9	76.3	81.2	81.5	80.4	74.2	33.7	73.1	77.4	76.9	74.2	72.0		13.5	13.8	14.3	15.0	22.2	15.4	14
15	46.3	41.7	48.4	60.0	37.9	27.4	48.4	76.7	73.9	45.3	47.8	49.5	81.6	84.9		47.1	35.7	40.6	74.1	50.0	15
16	54.2	54.1	54.1	61.2	55.4	50.6	57.0	74.7	74.7	51.8	27.6	58.1	79.5	83.5	44.0		44.0	41.4	33.3	31.0	16
17	55.6	56.6	61.4	67.5	59.3	55.6	68.7	80.8	81.9	59.0	56.0	68.7	87.2	83.3	58.5	54.4		56.0	25.9	35.7	17
18	51.0	56.1	58.2	59.5	51.0	45.8	53.5	75.3	69.1	56.1	42.9	52.5	77.5	78.7	48.9	51.8	40.2		44.4	46.0	18
19	11.1	11.1	14.8	57.1	18.5	14.8	25.9	68.0	51.9	14.8	37.5	29.6	55.6	72.0	13.0	35.7	57.9	41.7		81.5	19
20	50.5	52.4	53.4	61.6	45.5	49.5	38.5	71.0	73.7	48.5	57.6	38.5	75.5	74.2	48.4	62.8	61.4	48.5	18.5		20
	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	

EG3IN.PRO
FUSEQIN.PRO
GLIOIN.PRO
ACRHYPO.PRO
ASPKAWA1.PRO
ASPACU1.PRO
HUMIN.PRO
11AG8IN.PRO
ERWCARIN.PRO
GLIO314.PRO
GLIO3HYP.PRO
HGRIS.PRO
RHMARIN.PRO
SLVIN.PRO
PENNOT.PRO
PHANHYPO.PRO
F42HYPO.PRO
EMDESHYP.PRO
MYCINS.PRO
CHBRAS.PRO

PERCENT SIMILARITY

FIG.-4

PERCENT DIVERGENCE

6/8

PCT/US 98/26552

09/284327

FIGURE 6

	1	60
T. reesei	M.....KF.LQVLPALIPAALAOQS.....	CDQWATFTGNG..YTV
H. schweinitzii	M.....KF.LQVLPAILPAALAOQS.....	CDQYATFTSGNG..YIV
A. aculeatus	M.....KAFHL.LAALAGAAVAQQAQ.....	LCQYATYTTGGV..YTI
A. kawachii	M.....KLSMT.LSLFAATAMQOT.....	MCSQYDSASSPP..YSV
A. kawachii_2	M.....KAFHL.LAALSGAAVAQQAQ.....	LCQYATYTTGGV..YTI
A. oryzae	M.....KLSLA.LATLVATAFSQE.....	LCQAQYDSASSPP..YSV
H. grisei	M.....LKSALLLGAASVQSASIPTIPANLEPRQIR.SLCELYGYWSGNG..YEL	
H. insolens	M.....LKSALLLGPAAVSVQSASIPTIPANLEPRQIR.SLCELYGYWSGNG..YEL	
Chaetomium brasiliense	M.....KLTLVLVFSLLA.....AATPLGWRRQQVSLCGQSSWSGNG..YQL	
F. equiseti	M.....KSTLLLAGAFAPLAFAD.....	LCEQYGLSSDG..YSL
F. javanicum_1	M.....KSAIVA.ALAGLAAASPTRLIPRGQ.....	FCGQWDSSETAGA..YTI
F. javanicum_2	M.....K.FFGVVSASLAATAVATPTTPTETIEKRDTTWCDAFGSLATSG..YTV	
G. roseum_1	M.....KANIVILSLFAPLAAVAQT.....	LCQYSSNTQGG..YIF
G. roseum_2	M.....KSIISFFGLATLVAAAPSONPRTTQPLEKRATTLCGQWDSVETGG..YTI	
G. roseum_3	M.....KFQLLSLTAFAPLSLAA.....	LCQYQSQSQGG..YIF
G. roseum_4	M.....KTGIAYLAAPLPLA.MAES.....	LCQYAYLSRDG..YNF
Memnoniella echinata	M.....KVAAL.LVALSPLAF.AQS.....	LCQYSSYSSNG..YEF
Emericella desertoru	M.....K.LLALSLSVLSASAASAIL.SNTFTRRSD.FCGQWDTATVGN..FTIV	
Actinomyces_11AG8	MRS.....HPRS..ATM.TVLVVLASLGALLTAAAPAAQANQQICDRYGTTTIQD.RYVV	
S. lividans_CelB	MRTLRLPQARAPRGLAALGAVLAALFVSSLVTAAPAAQADTTICEPFGTTTIQG.RYVV	
Rhodothermus marinus	MNVMR..AVLVLSLLLLFGCDWL.FPDGDNKEPEPEPEPTVELCGRWDARDVAGGRYRV	
Erwinia carot	MQTVNTQPHRIFRVLPAVFSLLLLSLTSAASSNDADKLYF.....	GNNKYLL
	61	120
T. reesei	SNNLWGASAGSGF..GCV.TAVSLSGG.ASWHADWQWSGGQNNVKSQNS.....	
H. schweinitzii	SNNLWGASAGSGF..GCV.TSVSLNGA.ASWHADWQWSGGQNNVKSQNV.....	
A. aculeatus	NNNLWGKDGAGSG..SQCTTVNSASSAG.TSWSTKWNWSGGENSVKSYANS.....	
A. kawachii	NNNLWGEYQGTG..SQCVYVDKLSSSG.ASWHTKWTWSGGEGTKSYNS.....	
A. kawachii_2	NNNLWGKDGAGSG..SQCTTVNSASSAG.TSWSTKWNWSGGENSVKSYANS.....	
A. oryzae	NNNLWQDQSGTGFTSQCVYVDNLSSSG.AAWHTTWTWNGEGSVKSYNS.....	
H. grisei	NNNLWGKDTATS.GWQCTYLDGTNNGG.IQWNTAWEWQAGPDNVKNYPV.....	
H. insolens	NNNLWGKDTATS.GWQCTYLDGTNNGG.IQWNTAWEWQAGPDNVKNYPV.....	
Chaetomium brasiliense	NNNLWQQRATS.GSQCTYLDSSSSNG.IHWHTTWTWEGGEVKSYSYNS.....	
F. equiseti	NNNVWGKDSGTGD..QCTHVNWNANG.AGWDVEWNWSGGKDNVKSYPNS.....	
F. javanicum_1	YNNLWGKDAES.GEQCTNSGEQSDGSIAWSVSWTGGQGVKSYPNA.....	
F. javanicum_2	YHNNWGKGDATS.GSQCTTFTSVSNNFV.WSTSWTWAGGAGKVSYPNV.....	
G. roseum_1	NNNMWGMGSGSGS..QCTYVDKVAEG.VAWHTDWSWSGGDNNVKSYPNS.....	
G. roseum_2	YNNLWQDNG.S.GSQCLTVEGV.TDGLAASSTWSWSGGSSSVKSYSNA.....	
G. roseum_3	NNNKWQCGSGSGS..QCLTIDKTWDSN.VAFHADWSWSGGTNNVKSYPNA.....	
G. roseum_4	NNNEWGAATGTGD..QCTYVDSTSSSG.VSWHSDWTWSGSESEKSYPS.....	
Memnoniella echinata	NNNMWGRNSGQGN..QCTYVDYSSPNG.VGWRVNNWSGGDNNVKSYPNS.....	
Emericella desertoru	YNNLWQDNADS.GSQ..TGVDANGNSISWHTTWSWSGGSSSVKSYSNA.....	
Actinomyces_11AG8	NNRWGTSAT.....QCINVT..GNGFEITQADGS..VPTNGAPKSYPSVYDCHYG...	
S. lividans_CelB	QNNRWGSTAP.....QCVTAT..DTGFRVTQADGS..APTNGAPKSYPSVFNCHYT...	
Rhodothermus marinus	INNVMGAETA.....QCIEVLETGNFTITRADHD..NGNNVA..AYPAIFGCHWAPAR	
Erwinia carot	FINNVGKDEIKGWQQTIFYNPSISMG...WN..WHWPSTHSVKAYPSLVSGWHWTAG.	
	121	180
T. reesei	.QIAIP.QKRTVNSISSMPTTASW...SYSGSNIRANVAYDL.FTAANPNHVTYSGDYEL	
H. schweinitzii	.QINIP.QKRTVNSIGSMPTTASW...SYSGSDIRANVAYDL.FTAANPNHVTYSGDYEL	
A. aculeatus	.GLTF..NKKLVSQISQIPTTARW.S..YDNTGIRADVAYDL.FTAADINHVTWSGDYEL	
A. kawachii	.GLTF..DKKLVSQISQIPTSVTW.SQD..DTNVQADVSYDL.FTAANADHATSSGDYEL	
A. kawachii_2	.GLSF..NKKLVSQISQIPTTARW.S..YDNTCIRRGAYDL.FTAADINHVTWSGDYEL	
A. oryzae	.AVTF..DKKLVSQISQIPTDVEW.SQDFTNTNVNADVAYDL.FTAADQNHVTYSGDYEL	
H. grisei	.GKQIQGRK.ISDINSMTSVSW...TYDRTDLRANVAYDV.FTARDPDHNPWGGDYEL	
H. insolens	.GKQIQGRK.ISDINSMTSVSW...TYDRTDLRANVAYDV.FTARDPDHNPWGGDYEL	
Chaetomium brasiliense	.GROVSTGLT.IASIDSMQTSVSW...EYNTTDIQANVAYDI.FTAADPNHETSSGDYEL	
F. equiseti	.ALLIGEDKKTISSITNMOSTAEW...KYSQDNLRADVAYDL.FTAADPNHETSSGEYEL	
F. javanicum_1	.VVEI..EKKTLGEVSSIPSA..W.DWTYTGNGIIANVAYDL.FTSSTESGDA...EYEF	
F. javanicum_2	.ALEK..INKKISDIKSVSTR..W.IWRYTGTKMIANVSYDL.WFAPTASSNN...AYEI	
G. roseum_1	.GRELGT.KRIVSSIKSISGADW...DYTGSNLRANAAYDI.FTSANPNHATSSGDYEV	
G. roseum_2	.VLSA..EAARISAISSIPSK..W.EWSYTGTDIVANVAYDL.FSNTDCGDTPT...EYEI	
G. roseum_3	.GLEFSR.GKKVSSIGTINGADW...DYSGSNIRANVAYGI.FTSADPNHVTSSGDYEL	
G. roseum_4	.GLDLPE.KKIVTSIGSISTGAEW...SYSGSDIRADVAYDT.FTAADPNHATSSGDYEV	
Memnoniella echinata	.GRQLPT.KRIVSWIGSLPTTVSW...NYQGNLNRANVAYDL.FTAANPNHNPSSGDYEL	
Emericella desertoru	.AYQF..TSTKLSLSISPTS..W.KWQYSTTDIVANVAYDL.FTSSSAGGDS...EYEI	
Actinomyces_11AG8	...NCAPRTTLPRISSIGSAPSSVSRYTNGVY.NAAYDIWLDPTPTNGVNR..TEI	
S. lividans_CelB	...NCSPGTDLPVRLDPTVSAAPSSISYGFVDGAVY.NASYDIWLDPTARTDGVNQ..TEI	
Rhodothermus marinus	AIRDCAARAGAVRRRAHEDVTP.....ITTGRW.NAAYDIWFSPTVNSGNGYSGGAEL	
Erwinia carot	...YTENSGLPQLSSNKSITSNTVYSIKATGY.NAAYDIWFHTTDKANWSSPTDEL	
	181	240
T. reesei	MIWLKGYGDIGPIGSS...QGTVNVGGSQSWTLYGYNGAMQV.....YSFVAQT.NTT	
H. schweinitzii	MIWLKGYGDIGPIGSS...QGTVNVGGSQSWTLYGYNGAMQV.....YSFVAQS.NTT	
A. aculeatus	MIWLARYGQVPIGSG...IATATVDGQTWELWYG.....ANGSQYTSFVAPT.PIT	
A. kawachii	MIWLARYGQVPIGSG...IATATVGGKSWEVW..YGTSTQAGAEQKTSYFVAGS.PIN	
A. kawachii_2	MIWLARYGGVPLGSG...IATATVEGQTWELWYG.....VNGAQKTSYFVAAN.PIT	

09/24/37

MIWLARYGTIQPIGQ...IDTATVEGHTWELWFTYGTITQAGAEQKTSYFSVSAT.PIN
MIWLARYGGIYPIGTF...HSQVNLAGRTWDLWFGYNGNMVR...YSFLPPSGDIR
MIWLARYGGIYPIGTF...HSQVNLAGRTWDLWFGYNGNMVR...YSFLPPSGDIR
MIWLARYNNVSPIGSS...VATATVGGDTWDLFAGANGDMEV...YSFVAENT.MN
MWLARIGGVQIGSL...QTSVITEGHTWELWVNGMSMKV...FSFVAPT.PVN
MIWLSALGGAGPISSTGSP.VATAELAGTSWKLLQCKNNQMTV...FSFVAESD.NV
MIWVGAYGGALPISPTGKGVIDRPTLKAIPWDVYKGPNGDVTV...ISFVASSNQ.G
MIWLANLGGTLPIGSP...IGTVKAAGRDWLDVGYNGAMRV...YSFVAPS.QLN
MIWLSALGGAGPISSTGSS.IATVTIAGASWNLWQCGNNQMAV...FSFVAESD.KV
MIWLGKGLDIYPIGNS...IGRVAAANREWDFLVGYNGAMKV...FSFVAPS.PVT
MIWLANLGGTLPIGSP...IGTVKAAGRDWLDVGYNGAMRV...YSFVAPS.QLN
MIWLGRLGNVYPIGNQ...VATVNIAGQOWNLYGYNGAMQV...YSFSPVN.QLN
MIWLAALGGAGPISSTGSS.IATVTLGGVTWSLYSGPNGSMQV...YSFVASSTT.E
MIWFNRVGPVQPIGSP...VGTHVGGRSWEVWTFSGNSGNDVI...SFLAPS.AS
MIWFNRVGPQPIGSP...VGTSVGGRTWEVWSGGNGSNDVL...SFFVAPSA.IS
MIWLNNGGVMGPGSSR...VATVELAGATWEVWYADWDNYNTA...YRTRTPT.TS
MIWLNDNTA...GPAGDYIETVFLGDSNNVFKGIWINADN.GGGWNVFSFHTTSGTNS

241 300

NYSGDVKNFFNYLRDNKGYNAAQQYV. .LSYQFGTEPF. .TGSQT.LNVASWTASI.N.
SYSGDVKNFFNYLRDNKGYNAAQQYV. .LSYQFGTEPF. .TGSQT.LNVASWTASI.N.
SFQGDVNDFFKYLTQNHGFPASSQYLI. .TLQFGTEPF. .TGGPATLSVNSWASVQQAG
SWSGDIKDFFNYLTQNGFPASSQHLI. .TLQCGTEPF. .TGGPATFTLVNDWTASVN. .
SFQGDINDFFKYLTQNHGFPASSQYLILALQFGTEPF. .TGGPATLVNDWASASVQ. .
TFGGDIKKDFPDIYSKHSFPAASQYLI. .NMQFGTEPFPTTGGPVTFTVPNWTASVN. .
DFSCDIKDFFNYLERNHGYPAEQNLIV. .YQVGTECF. .TGGPARFTCRDFRADL. .
DFSCDIKDFFNYLERNHGYPAEQNLIV. .YQVGTECF. .TGGPARFTCRDFRADL. .
SFSGDVNDFFDYLEQNVGFPVDDQYLLV. .FLGSEAF. .TGGPATLSVSQFSANI. .
NFNADIKQFDWYLTQSNQFPADNQYL. .LTFQFGTEPF. .TGDNAKFTVTNFAHLK. .
NFCGLDAFTFDYLVNDHGVSSSQ. .ILQSVQAGTEPF. .EGTNVAVFTNNYHADVE. .
NFGADIKFEFLNLYTSKQGLPSNY. .VATSFQAGTEPF. .EGTNVAVLTSAYTSIVSN. .
SFDGEIMDFFYVVKDMRGFPADSOHL. .LTVQFGTEPI. .SGSGAKFSVSHWSAKLG. .
SFSGDINDFFIYQLVDSQSGSGSQ. .CLYSIGAGTEPF. .TGTDAEFTTGYSVSVSAGD
LFDGNIMDFFYVVMRDMQGYPMKDQYL. .LSLQFGTEPF. .TGSNANFSCWYFGAKIK. .
SFDGEIMDFFYVVKDMRGFPADSOHL. .LTVQFGTEPI. .SGSGAKFSVSHWSAKLG. .
YFSGDNDMDFFTYLQYNRAYPADSOYL. .ITYQFGTEPF. .TGNQNAVFTVSNWSAQQNN. .
SFSADLMDFINYLAEQGLSSSQ. .YLTHVQAGTEPF. .TGTDATLTVSSYSVSVS. .
SWSFDVKDFVD. .QAVSHGLATPDWYLT. .SIQAGFEPW. .EGGTGLAVNPFSSAVNAG.
GWSFDVMDFVR. .ATVARGLAENDWYLT. .SVQAGFEPW. .QNGAGLAVNPFSSVTETGT
VSELDKAFID. .DAVARGYIRPEWYLT. .AVETGFEWLW. .EGGAGLRTADPFSVTVQ. .
A. .SLNIRHPTDYLVTQKQWMSDEKYIS. .SVEPGETEIF. .GGDGQIDITEWRVDVK. .

```

301                                     360
.....
F.....EPWQNGAGLAVNSF.....
.....
.....W.....
.....W.....
.....A.....
.....
.....
SGCDETTTSSQAQSSTVETSTATQPQS...SSTVVPTVTLS.QPSNESTTPVQSQ...
.....
.....
..GGNGGTPGTAAACQVSYSTHTWPGGFTVDTTITNTGSTPVDGWELDFTLPAIGHTVTSFA
PGGTDPGDPGGPSACA VSYGTNVWDGFTADVTVTNTGTAPVDGWQLAFTLP SGQRITNA
.....

```

361

SSTV.....Y


PSSVETTPTAQPQSSSVQTTTTAAQ...QPTSGTGCSRRLRRR....AVV

Fig 6 (continued)

G._roseum_4
Memnoniella_echinata
Emericella_desertoru
Actinomycete_11AG8	WNALISPASGAVTARSTGSGNGRIAANGGTQSFQGTSSGTGFNAPAGGRLNGTSCTVR
S._lividans_CelB	WNASLTPSSGSVTATGASHNARIAP.GGSLSFQGTGTYGGA.FAEPTGFRLNGTACTTV
Rhodothermus_marinus
Erwinia_carot

09/284327

Fig 6 (continued)

Please type a plus sign (+) inside this box → 

PTO/SB/01 (12-97)

Approved for use through 9/30/00. OMB 0651-0032

Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

DECLARATION FOR UTILITY OR DESIGN PATENT APPLICATION (37 CFR 1.63)

☒ Declaration Submitted with Initial Filing OR ☐ Declaration Submitted after Initial Filing (surcharge (37 CFR 1.16 (e)) required)

Attorney Docket Number	GC516-2-US
First Named Inventor	Benjamin S. Bower
COMPLETE IF KNOWN	
Application Number	/
Filing Date	
Group Art Unit	
Examiner Name	

As a below named inventor, I hereby declare that:

My residence, post office address, and citizenship are as stated below next to my name.

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled:

Benjamin S. Bower, 320 Esplanade Drive, Apt.39, Pacifica,
California 94044

the specification of which (Title of the Invention)

☐ is attached hereto
OR

☒ was filed on (MM/DD/YYYY) 12-14-98 as United States Application Number or PCT International

Application Number PCT/US98/26552 and was amended on (MM/DD/YYYY) (if applicable).

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment specifically referred to above.

I acknowledge the duty to disclose information which is material to patentability as defined in 37 CFR 1.56.

I hereby claim foreign priority benefits under 35 U.S.C. 119(a)-(d) or 365(b) of any foreign application(s) for patent or inventor's certificate, or 365(a) of any PCT international application which designated at least one country other than the United States of America, listed below and have also identified below, by checking the box, any foreign application for patent or inventor's certificate, or of any PCT international application having a filing date before that of the application on which priority is claimed.

Prior Foreign Application Number(s)	Country	Foreign Filing Date (MM/DD/YYYY)	Priority Not Claimed	Certified Copy Attached?	
PCT/US98/26552	PCT	12-14-98	<input type="checkbox"/>	YES <input type="checkbox"/>	NO <input checked="" type="checkbox"/>
			<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
			<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
			<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>

☐ Additional foreign application numbers are listed on a supplemental priority data sheet PTO/SB/02B attached hereto:

I hereby claim the benefit under 35 U.S.C. 119(e) of any United States provisional application(s) listed below.

Application Number(s)	Filing Date (MM/DD/YYYY)	
		<input type="checkbox"/> Additional provisional application numbers are listed on a supplemental priority data sheet PTO/SB/02B attached hereto.

[Page 1 of 2]

Burden Hour Statement: This form is estimated to take 0.4 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

SCANNED, # 12

Please type a plus sign (+) inside this box →



Approved for use through 9/30/00. OMB 0651-0032
 Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
 Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

DECLARATION — Utility or Design Patent Application

I hereby claim the benefit under 35 U.S.C. 120 of any United States application(s), or 365(c) of any PCT international application designating the United States of America, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States or PCT international application in the manner provided by the first paragraph of 35 U.S.C. 112, I acknowledge the duty to disclose information which is material to patentability as defined in 37 CFR 1.56 which became available between the filing date of the prior application and the national or PCT international filing date of this application.

U.S. Parent Application or PCT Parent Number	Parent Filing Date (MM/DD/YYYY)	Parent Patent Number (if applicable)
PCT/US98/26552	12-14-98	

☐ Additional U.S. or PCT international application numbers are listed on a supplemental priority data sheet PTO/SB/02B attached hereto.

As a named inventor, I hereby appoint the following registered practitioner(s) to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith:

☐ Customer Number OR ☒ Registered practitioner(s) name/registration number listed below

Name	Registration Number	Name	Registration Number
Christopher L. Stone	35,696		

☐ Additional registered practitioner(s) named on supplemental Registered Practitioner Information sheet PTO/SB/02C attached hereto.

Direct all correspondence to: ☐ Customer Number or Bar Code Label OR ☒ Correspondence address below

Name	Christopher L. Stone				
Address	Genencor International, Inc.				
Address	925 Page Mill Road				
City	Palo Alto	State	CA	ZIP	94304-1013
Country	USA	Telephone	(650) 846-7555	Fax	(650) 845-6504

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under 18 U.S.C. 1001 and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Name of Sole or First Inventor: ☐ A petition has been filed for this unsigned inventor

Given Name (first and middle [if any])		Family Name or Surname	
Benjamin S.		Bower	
Inventor's Signature	<i>Benjamin S. Bower</i>		Date
Residence: City	Pacific	State	CA
		Country	USA
Post Office Address	320 Esplanade Drive, Apt.39		
Post Office Address			
City	Pacific	State	CA
		ZIP	94044
		Country	USA

☒ Additional inventors are being named on the _____ supplemental Additional Inventor(s) sheet(s) PTO/SB/02A attached hereto



SCANNED, # 12

Please type a plus sign (+) inside this box → ☐

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Approved for use through 9/30/98. OMB 0651-0032
Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

DECLARATION	ADDITIONAL INVENTOR(S) Supplemental Sheet Page <u>3</u> of <u>3</u>
--------------------	--

Name of Additional Joint Inventor, if any:		<input type="checkbox"/> A petition has been filed for this unsigned inventor			
Given Name (first and middle [if any])		Family Name or Surname			
<u>Timothy</u>		<u>Fowler</u>			
Inventor's Signature				Date	<u>4/2/99</u>
Residence: City	<u>San Carlos</u>	State	<u>CA</u>	Country	<u>USA</u>
				Citizenship	<u>UK.</u>
Post Office Address	<u>1979 Eaton Avenue</u>				
Post Office Address					
City	<u>San Carlos</u>	State	<u>CA</u>	ZIP	<u>94070</u>
				Country	<u>USA</u>
Name of Additional Joint Inventor, if any:		<input type="checkbox"/> A petition has been filed for this unsigned inventor			
Given Name (first and middle [if any])		Family Name or Surname			
<u>Jay I</u>		<u>Phillips</u>			
Inventor's Signature				Date	<u>4/2/99</u>
Residence: City	<u>Palo Alto</u>	State	<u>CA</u>	Country	<u>USA</u>
				Citizenship	<u>USA</u>
Post Office Address	<u>785 Barron Avenue</u>				
Post Office Address					
City	<u>Palo Alto</u>	State	<u>CA</u>	ZIP	<u>94306</u>
				Country	<u>USA</u>
Name of Additional Joint Inventor, if any:		<input type="checkbox"/> A petition has been filed for this unsigned inventor			
Given Name (first and middle [if any])		Family Name or Surname			
Inventor's Signature				Date	
Residence: City		State		Country	
				Citizenship	
Post Office Address					
Post Office Address					
City		State		ZIP	
				Country	

Burden Hour Statement: This form is estimated to take 0.4 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

SCANNED: # 12